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ABSTRACT

The multidisciplinary field of nanotechnology has allowed for unprecedented
exploration and manipulation of molecular, sub-molecular, and atomic structures and
advancements in this field are revolutionizing scientific thought and applications. Within
the field of nanotechnology, the branch of nanobiotechnology focuses on studying the
effects of nanomaterials on biological systems and to elucidate how nanomaterials
interact with cells and cellular components. Nanoparticles are a particular type of
nanomaterial whose dimensions measure 100 nanometers and are shown to possess
unique size-dependent physical, chemical and biological properties compared to their
bulk counterparts. Metal oxide nanoparticles, such as those made from ZnO, are a type of
nanomaterial found in many different industrial products such as sunscreen, food
preservatives and clothing. Due to the prevalence of ZnO nanoparticles in the
environment, there is an urgent need to gain an understanding of how these particles
interact with biological systems, and due to the fact that nanoparticles are within the
range of many different naturally occurring biological molecules, research investigating
nanoparticle-cell interactions may offer innovative approaches for the development of
novel biomedical applications.
This research focuses on examining the effects of metal oxide based
nanoparticles, including ZnO, on immune cells and investigates cell-specific responses
viii

and mechanisms of toxicity. Collectively, our results demonstrate differential ZnO NP
toxicity based on cell-type, activation status, and NP size with highly proliferative/rapidly
diving cells (e.g. cancer cells and activated T cells) killed at lower concentrations of ZnO
nanoparticles compared to normal cells. In addition, an inverse relationship between
nanoparticle size and cytotoxicity was observed. Further, these results implicate ROS
production as a major mechanism of ZnO-NP induced cytotoxicity capable of inducing
apoptosis in human immune cells, and reveal ZnO NP induce pro-inflammatory cytokine
production (e.g. IFN-, TNF-α and IL-12). Exploitation of the preferential nanoparticlemediated toxicity observed in these studies may provide a foundation for the design and
development of novel ZnO nanoparticle based biomedical applications and therapeutics
for the treatment of human diseases, such as cancer and autoimmune disorders.
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INTRODUCTION

Scientific advancements in biology and biotechnology have enabled the molecular
and sub-molecular examination of intracellular dynamics and intercellular interactions,
resulting in the development of new and improved biomedical devices and therapeutic
interventions. The ability to investigate sub-atomic, atomic and molecular materials and
structures has led to the emerging field of nanotechnology, a multidisciplinary industry
concerned with researching, developing and utilizing nanometer (nm) sized materials. As
many naturally occurring biological structures are found in the nanometer range, the
integration of biology and nanotechnology provides a platform by which significant
contributions to the development of new diagnostic agents and devices, and targeted
therapeutic treatments may be achieved. Nano-sized materials, such as nanoparticles
(NP), can exhibit unusual properties such as alterations in chemical reactivity and other
physical characteristics not predicted for larger particles made from the same material
(Feringa 2000). The altered properties of NP, coupled with their similarity in size to
many biological structures, allow for their interactions with biomolecules both on the cell
surface and within the cell, and may potentially affect cellular responses in a dynamic
and selective manner. As such, it is necessary to identify and characterize the effects of
NP on various biological systems and cell types and evaluate the possibility of exploiting
NP for use in novel biomedical applications.
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Nanotechnology and Nanomaterials
Nanotechnology encompasses many different scientific disciplines, including
computer science, engineering, physics, chemistry and biology, and has revolutionized
scientific applications in all these areas. Explosive growth in the field of nanotechnology
has resulted in phenomenal global market spending on research and products, increasing
from $8.6 billion in 2004 to upwards of $18 billion in 2008 (approximately $8.4 billion in
government funding, $8.4 billion in corporate funding and $1.6 billion in venture
capitalist funding), and is estimated to exceed more than $2.5 trillion dollars worldwide
by the year 2014 (Lux Research Inc 2009). In response to this rapid growth and the
widespread use of nano-based products, federally funded organizations, such as the
National Nanotechnology Initiative (NNI), have been created to monitor and support the
research and development of nanomaterials and nanostructures. As stated in the White
House press release upon the formation of the NNI, ―These developments [in
nanotechnology] are likely to change the way almost everything - from vaccines to
computers to automobile tires to objects not yet imagined - is designed and made‖ (NNI
2009).
Unlike bulk materials, whose behaviors are dictated and predicted based on the
laws of classical physics and the properties of individual molecules, the properties and
characteristics of nanomaterials are governed by laws of both quantum and classical
physics. This phenomenon is attributed to ―quantum effects‖ in which the behaviors of a
materials are altered in response to significant reductions in material size (Singh and
Nalwa 2007). As the size of a material is reduced to the nano-scale, there is an increase in
the surface area to volume ratio, and a greater percentage of atoms are expressed on the
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surface of nanomaterials compared to micron-sized bulk materials (Cao 2004). The
consequences of this phenomenon are the unique properties observed in many
nanomaterials such as changes in reactivity, conductivity, and light diffraction. An
example of these changes is illustrated when comparing the properties of bulk copper
compared to nano-sized copper structures. Although bulk copper (e.g. wire, ribbon, etc.)
is malleable and highly conductive, when reduced to the nano-scale (less than 50 nm)
copper loses both its malleability and conductive abilities (Takata, Lee, Lim, Kim and
Tsuji 2007). Another example is the discrepancy observed in suspensions of alumina NP,
which have been shown to have increased thermal conductivity compared to suspensions
of micron-sized alumina particles (Oesterling et al. 2008).
The term ―nanotechnology‖ is a 20th century idiom, however evidence for
utilization of nanomaterials can be found in early civilization artifacts. Archaeologists
and museum scientists have discovered that 10th century Persian artisans used metallic
(e.g. silver and copper) NP in ceramic glazes to give the pottery an illustrious and
iridescent finish, with results dependent on size, shape, and the distribution of the
metallic clusters in the glaze (Erhardt 2003). This technique, which spread throughout
Europe by the 14th century, was accomplished by the breakdown of metal salts and oxides
during the firing process (Erhardt 2003). Although the molecular basis for the distinctive
properties exhibited by these nanomaterials (namely, increased optical refractivity and
surface reactivity) was not understood at the time, modern science has revealed these
desirable qualities are ascribed to the nanometer-sized particles found in these glazes.
The central scientific concepts which led to the creation of nanotechnology were
first described by Scottish physicist, James Clerk Maxwell, in 1867, whose work
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revolutionized theories explaining the laws of thermodynamics and electromagnetic
behavior (Maxwell and Niven 2003). His theories, stating that molecular movement is
predicted by the laws of probability, and not certainty, created a foundation upon which
nanotechnology was developed (Maxwell and Niven 2003). From that time through the
first quarter of the 20th century, significant progress was made towards the understanding
of atomic/sub-atomic behavior, all of which contributed to the concepts upon which
nanotechnology is built. However, it was a seminar given by Richard Feynman in 1959
entitled ―There’s Plenty of Room at the Bottom‖ which is credited as catalyzing the
creation of nanotechnology (Wilkinson 2004). In this presentation, Dr. Feynman
discussed the possibility of manipulating materials at the atomic and molecular scale, and
addressed the potential issues associated with this, such as the fact that matter on this
scale behaves differently than it would on a larger scale (Feynman 1959).
Nanomaterials and nano-based products are becoming increasingly prevalent and
can already be found in a variety of different industrial applications, ranging from
electronics and laser-based applications to anti-microbial band-aids and anti-reflective
coatings for glass (Osman, Rardon, Friedman, and Fanor-Vega 2006). Specific types of
nanomaterials, such as those made from metal oxides, have been found to possess
specific properties, such as increased conductivity, changes in color and transparency,
which make them useful in a wide-range of industrial products, including water-repellent
clothing, biosensors, electronics and cosmetics (Cao 2004).
ZnO is a type of naturally occurring metal oxide frequently found in a variety of
different products such as paints, adhesives, sunscreens, cosmetics, and as an antimicrobial agent in ointments and rubber (Nohynek, Dufour and Roberts 2008). When
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reduced to the nano-scale, ZnO exhibits distinctive optical and electronic properties, and
demonstrates superior transparency and UV adsorption/blocking abilities compared to
bulk ZnO (Cross, Innes, Roberts, Tsuzuki, Robertson and McCormick 2007). Due to the
increasing use of nanomaterials in industrial applications, a thorough understanding of
the mechanisms by which nano-sized materials interact and impact various cell types is
critical from both a toxicological standpoint and for enabling the discovery of potential
applications for these materials.

Nanobiotechnology and Nanoparticles
Nanobiotechnology is a specific branch of nanotechnology aimed at investigating
potential biological applications for nanomaterials and exploring how nano-sized
materials and structures interact with and affect biological systems (McNeil 2005). As
many important biological entities, such as DNA and proteins, fall within the nanometer
size range, nanomaterials (e.g. NP) are being designed to interact with specific biological
components allowing for improved precision and efficiency in molecular manufacturing
and control. The use of nanomaterials in biological applications may provide new
approaches and exciting possibilities for genomics, information storage, energy
conservation and medicine. Current applications under investigation include biosensing,
tumor imaging, and targeted drug delivery (e.g. antibody-NP conjugates) (Angeli et al.
2008; Dinauer, Balthasar, Weber, Kreuter, Langer and von Briesen 2005). Researching
new applications for different types of nanomaterials in a biological context is an integral
part of nanobiotechnology, and exploiting the specific properties of nanomaterials may
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enable new approaches for manipulating and eliciting specific biological responses
(Lowe 2000).
NP (particles 100 nm or less in any two dimensions) are among the nanomaterials
that may be best suited for biological applications due to their size being in the range of
many biological entities and their unique size-dependent properties (Zhang, Gu, Chan,
Wang, Langer and Farokhzad 2008). NP are highly diversified, come in a variety of
different shapes and sizes and are made from an assortment of materials. All these factors
contribute to the unique size-dependent physical, chemical, and biological properties
observed in NP which distinguish them from their micron-sized bulk counterparts
(McNeil 2005). Additionally, many types of NP have a propensity to form micrometersized aggregates (called nanopowders), which affect both the solubility and behavior of
these materials (Roca and Haes 2008). Metal oxide NP, in particular, have wide-spread
applications and are frequently found in many different commercial products ranging
from sunscreens and cosmetics (e.g. TiO2, Fe3O4 and ZnO) to dental fillers (e.g. SiO2)
and photovoltaic cells (e.g. CdS, CdSe and ZnS) (Brayner, Ferrari-Iliou, Brivois, Djediat,
Benedetti and Fievet 2006; Donaldson 2006).
Examples of some NP dependent properties include superparamagnetism
observed in certain types of magnetic NP, surface plasmon resonance in various metal
NP, and the quantum confinement of semiconductor NP (Donaldson 2006). These
differences are further illustrated in the altered characteristics observed in gold NP which
appear reddish-black in color and are capable of conducting electricity, compared to
micron-sized bulk gold which is yellow in color and non-conductive (Wilson 2008). The
distinctive chemical and physical properties observed in NP warrants further
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investigation into the biological effects of specific types of NP to various cellular systems
and cell types under physiologically relevant conditions and identifying different types of
NP suited for biological applications (Schmid 2004). To this end, much research is being
conducted to evaluate potential biological applications for various types of NP, ranging
from drug delivery and biosensing to even utilizing NP as drugs themselves (BoguniaKubik and Sugisaka 2002). Examples of NP specifically useful for biotechnology and
nanomedicine include fullerenes (e.g. bucky balls and carbon tubes), liposomes,
nanoshells, dendrimers, nanorods, superparamagnetic NP, and quantum dots (QDs)
(Roco 2003).
QDs, or nanocrystals, are semiconductor NP (e.g. CuO2, Fe2O3, Au, ZnO, etc.)
being explored for biotechnological applications, specifically for use in biosensing, celllabeling/tumor imaging and drug delivery due to their distinctive electronic and
fluorescent properties and reduced tendency to photobleach (Vashist, Tewari, Bajpai,
Bharadwaj and Raiteri 2006). The novel properties possessed by QDs are due to valence
electron band holes, or excitons, which are confined in all three spatial dimensions in
these particles (Ashammakhi 2006). As many types of metal NP and metal oxide NP are
QDs, these NP (e.g. ZnO NP) are gaining recognition and utility not only for expansion
on traditional applications, but also for new biomedical purposes.

Nanomedicine and Biomedical Applications of NP
Nanomedicine is similar to nanobiotechnology in that both encompass
investigating the impact of nanomaterials on biological systems. However, nanomedicine
specifically describes the intersection of nanotechnology and medical science, and is
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focused on developing and utilizing nanomaterials to target specific cellular and subcellular components for disease prevention, treatment and damaged tissue repair
(Moghimi, Hunter and Murray 2005; Ashammakhi 2006). In contrast to many
conventional therapeutics (e.g. radiation, chemotherapy and surgery), nanomedicine
offers highly selective approaches to eliminate or repair specific cells and examples of
the types of nanomedicines under investigation include NP biological mimetics, the
creation of ―nanomachines‖ (e.g. structures made from interchangeable DNA parts and
DNA scaffolds), nano-scale devices used for drug release, biosensors for use in
laboratory diagnosis (e.g. QD), polymetric nano-constructs for use as molecular switches,
tissue engineering, and creating NP-antibody conjugates for targeted delivery of drugs,
genetic elements and diagnostic agents to specific cells and tissues (Navalakhe and
Nandedkar 2007; Riehemann, Schneider, Luger, Godin, Ferrari and Fuchs 2009).
Additionally, NP may be useful modalities for targeting and killing specific disease
causing cells (e.g. tumor and auto-reactive cells) while leaving normal cells and tissues
unharmed, and with fewer adverse side effects compared to conventional treatments
(Cho, Wang, Nie, Chen and Shin 2008).
Thus far, findings from several published in vitro studies examining the ability of
engineered NP to selectively destroy disease-causing pathogens and cancer cells have
revealed promising results (Emerich and Thanos 2007). One approach involves using
porous, biologically compatible ceramic NP (e.g. silica, alumina, titania, etc.) to
encapsulate anti-cancer photosensitive drugs (Salata 2004). Cytotoxicity is achieved
using a laser beam, which causes the photosensitive drugs to release reactive oxygen
species (ROS) which are cytotoxic to the targeted tumor cells, and surface modifications
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(e.g. attaching antibodies to the surface) allow targeted delivery and uptake of the
NP/drug complex to tumor cells (Salata 2004). Exploring different types of NP materials
for use in nanomedicines may reveal innovative methods for treating human diseases
such as cancer, autoimmune disease, neurodegenerative disorders and infection.
However, before any nanomedicine can be employed, a detailed understanding of how
NP interact and effect different types of cells is critical and is one of the major goals of
our research.

NP and Toxicity
The development and industrial exploitation of NP is progressing at an extremely
rapid rate and potential applications are being continually discovered. However,
information regarding mechanisms of NP toxicity to different cell types and biological
systems lags behind this prolific growth. Understanding the effects of NP on cell systems
is imperative as the unique behaviors and characteristics observed in many nano-sized
materials can potentially render an otherwise benign substance toxic to cells at the same
concentration (Nair et al. 2008). For example, a recently published study showed CdS NP
to be toxic to mammalian Chinese Hamster Lung (CHL) cells at lower concentrations
compared to micron sized CdS particles (Li et al. 2009). As with the introduction of any
new material that displays unusual and unorthodox behaviors, there is a need to increase
knowledge and awareness of the potential environmental impacts and toxic effects. The
toxicity of a given substance is monitored and recorded by the Federal Drug
Administration which has established a list of ―Generally Recognized as Safe‖ (GRAS)
substances which is a record of substances shown by rigorous in vitro and in vivo
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scientific studies to be safe under the conditions of their accepted use and are thus exempt
from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance
requirements (Angeli et al. 2008). Lately, concern has been raised over the evaluation
guidelines used to assess the safety of commonly accepted nano-sized GRAS substances,
as most toxicological data collected was conducted using bulk sized materials and did
not take the special characteristics of nanomaterials into consideration (Fischer and Chan
2007). Recently published research suggests NP toxicity is largely dependent on chemical
composition (e.g. subsequent ion dissolution and NP catalyzed cell-surface reactions),
potential for ROS formation, NP size/shape, and specific NP-cell interactions (Guo et al.
2008; Dobrovolskaia and McNeil 2007). As such, additional research is needed to
investigate the factors influencing NP toxicity to specific cell types and to elucidate
mechanisms of NP-induced cytotoxicity.
Although ZnO is a GRAS substance and has been shown to be relatively nontoxic
in bulk form (micron-sized particles and larger), recently published studies have
demonstrated ZnO NP toxicity in both eukaryotic and prokaryotic cell types. In one
study, researchers tested the effects of various metal oxide NP (e.g. TiO2, Al2O3, SiO2
and ZnO) to several strains of bacteria (E. coli, B. subtilis and P. fluorescens) and found
significant differences in toxicity in all metal oxide NP tested (except for TiO2) compared
to their respective micron-scaled counterparts. Interestingly, of all the metal oxide NP
types used in this study, ZnO NP were shown to be the most toxic to all bacterial strains
tested (Jiang, Mashayekhi and Xing 2009). Another recently published study found ZnO
NP display selective toxicity to different bacterial strains, namely increased susceptibility
in S. aureus compared to E. coli. In addition, this study demonstrated that prokaryotic
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cells were killed at lower concentrations of ZnO NP compared to primary human T cells
(Reddy, Feris, Bell, Wingett, Hanley and Punnoose 2007).
Other published studies examining the effects of metal oxide NP, specifically
ZnO NP, on eukaryotic cells have demonstrated significant cytotoxicity in various
mammalian cells, and research suggests the production of ROS may be a predominant
mechanism of toxicity (Limbach, Wick, Manser, Grass, Bruinink and Stark 2007). In
order to better predict toxic potential of NP due to oxidative stress, the hierarchical
oxidative stress model was developed which uses a three-tiered system based on the
levels of ROS produced in response to ZnO NP, CeO2 NP and TiO2 NP (Xia et al.
2008a). In tier 1, low levels of ROS produced initiate the upregulation of the Nrf2
transcription factor responsible for mediating the expression of antioxidant response
elements (ARE) in promoter phase 2 genes. This chain of events acts as a compensatory
mechanism to protect against ROS-induced cell damage. If exogenous sources of ROS
overwhelm tier 1 mechanisms, an inflammatory response is elicited in which ROS induce
redox-sensitive signaling pathways (e.g. MAP-kinases, NF-B cascades and proinflammatory cytokine expression such as IL-12, IFN- and TNF-α). Finally, if ROS are
produced in excess of what is required to induce a tier 2 response, mitochondrial inner
membrane electron transfer and permeability are disrupted, resulting in ROS-induced cell
death by both apoptotic and necrotic pathways.
Although ZnO NP have been shown to be toxic to eukaryotic cells, the majority
of research testing the ZnO NP toxicity to mammalian cells has been done on
immortalized cell lines and up until now, there have been only limited in vitro studies
evaluating ZnO NP cytotoxicity to primary human cells. Additionally, little is known
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about the factors influencing ZnO NP-mediated toxicity to specific immune cell types
such as ROS formation and mechanisms of ZnO NP-induced cell death (e.g. apoptosis
and necrosis). ZnO toxicity to both eukaryotic and prokaryotic cells has been established,
with varying toxicity thresholds observed for different strains of bacteria. Given the
integral role of the immune system in treating and preventing disease and maintaining
host integrity and the phenotypic diversity present amongst immune cells, it is reasonable
to assume not all immune cells will respond the same to ZnO NP treatment and is an
issue that requires further examination.

The Immune System and Host Health
The immune system acts to protect and defend animals from pathological,
potentially disease-causing entities such as viruses, bacteria, parasites, and
mutated/aberrant cells (i.e. cancer cells) by means of highly complex and tightly
regulated physical, chemical and biological mechanisms (U.S. Department of Health and
Human Services 2003). A key aspect of the immune system is the ability to distinguish
―self‖ from ―nonself‖, or put another way, the ability to recognize and ignore normal
healthy ―self‖ cells and to identify and destroy ―foreign‖ non-self cells and entities
(Mannie 1999). This requires the coordinated action of many different types of cells
called leukocytes, commonly known as ―white blood cells‖ (WBC). Immune system
malfunctioning results in the emergence of disease-processes such as autoimmune disease
(where the immune cells attack and destroy normal healthy tissue) or in the case of
immune system failure, the emergence of opportunistic infections and cancer (Cohn
2005). Evaluating the effects of commonly used NP, such as ZnO NP, on immune cells
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and elucidating mechanisms of immune cell-NP interactions may ultimately allow for
creating targeted NP treatments for these diseases and provides critical information on
how ZnO NP impact the human immune system.

Innate Versus Adaptive Immunity
The immune system is broadly broken up into two intricately related groups,
innate immunity and adaptive immunity (Huston 1997). Innate immunity refers to those
defense mechanisms which serve as the ―first line of defense‖ against foreign entities
upon initial exposure. Components of the innate immune system are preventive in nature
and are present before exposure to an infectious pathogen and are extremely fast in nature
(Uthaisangsook, Day, Bahna, Good and Haraguchi 2002). An important distinction
between innate and adaptive immune response is that innate immune mechanisms are
non-specific, as they do not recognize specific pathogens but rather provide general
barriers against infection or recognize general classes of molecular markers commonly
found on classes of pathological organisms (Uthaisangsook et al. 2002). Examples
include physical barriers such as the skin and mucous membranes, physiological barriers
such as temperature and pH, and biological barriers by way of cells that act to contain
and/or destroy pathogens and small non-cellular debris via internalization and the release
of various chemicals and cytokines (Mayer 2006). Additionally, the inflammatory
response acts as a barrier against foreign invasion by containment, activation, and
recruitment of immune cells to the area of infection (Mayer 2006).
When cells of the innate immune system recognize general ―foreign‖ proteins
they respond by either engulfment and intracellular destruction of the foreign material
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(called phagocytosis), or by direct killing processes using chemicals mediators injected
into target cells (Mayer 2006). After phagocytosis of a pathogen has occurred, a piece of
the pathogen (an antigen (Ag)) is expressed on the phagocyte cell surface in a process
known as Ag-presentation (Mayer 2006). Certain immune cells, namely dendritic cells
(DC), macrophages/monocytes and B cells are known as professional antigen presenting
cells (APC), and are responsible for presenting Ag to T lymphocytes (cells of the
adaptive immune response) and activating Ag-specific immune responses (Bowers
2006a). A crucial aspect of immune response involves the release of soluble proteins
called cytokines by immune cells in response to their encounter with foreign Ag, which
serve as a means of cell-to-cell communication and are critical for proper immune system
functioning (Mulloy and Rider 2006). Cytokines recognize and bind to specific receptors
found on the surfaces of neighboring cells (paracrine), cells located distantly (endocrine)
or on the secreting cell itself (autocrine) (Parkin and Cohen 2001). Binding of a cytokine
to its receptor causes cell ―activation‖, a process by which the cell progresses through the
cell cycle, divides and proliferates and carries out various biological processes. Cells of
the innate immune system include mast cells, eosinophils, basophils, neutrophils, DC,
macrophages/monocytes, and natural killer (NK) cells (Mayer 2006).
In contrast to innate immunity, adaptive immunity is highly selective and diverse,
and is capable of immunologic memory, a process by which arsenals of ―memory‖ cells
are formed for protection against future Ag exposure (Pancer and Cooper 2006).
Additionally, cells of the adaptive immune response, namely T and B cell lymphocytes,
are able to recognize and distinguish self from nonself (Pancer and Cooper 2006) and are
capable of recognizing an infinite number of Ag (molecular markers specific to a
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particular pathogen or foreign material) for the elimination of cells or entities displaying
the specific Ag (Pancer and Cooper 2006). Once a specific Ag has been encountered,
―memory‖ cells are created and remain dormant in circulation. In the event of a second
encounter with the same Ag, memory cells become activated and rapidly proliferate to
mount an attack against the foreign invader (Pancer and Cooper 2006). A functional
adaptive immune system requires cooperation between B cells and T cells. While B cells
serve as APC and produce Ag-specific antibodies to eliminate pathogens, T cells are
activated after recognizing Ag presented by APC (Krogsgaard and Davis 2005).
Although cells of the adaptive immune response are slower to take effect initially, once
activated they are powerful weapons in fighting infection and disease (Pancer and Cooper
2006). Our research focuses on the effects of ZnO NP on T cells, B cells, NK cells and
monocytes as a representative panel of immune cells with varying phenotypes and
diverse biological functions.

Mechanisms of Cellular-Uptake: Endocytosis and Phagocytosis
Endocytosis describes the active (ATP-dependent) process used by cells for
importing selected substances present in the extracellular environment (e.g.
macromolecules, pathogens, membrane lipids, integral proteins and other particulate
matter), and endocytic pathways are used by viruses, toxins and symbiotic microorganisms to gain entry into cells (Doherty and McMahon 2009). Endocytic mechanisms
serve many important cellular functions including the uptake of extracellular nutrients,
regulation of cell-surface receptor expression, maintenance of cell polarity, and
preservation of host health by eliminating potentially harmful bacteria and activating the
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immune response by Ag-presentation (Seabra, Mules and Hume 2002; Doherty and
McMahon 2009). During endocytosis, materials are taken into the cell by invagination of
the plasma membrane, resulting in the formation of new membrane-bound vesicles
containing the ingested substances (called endosomes), and are transported to various
intracellular locations including digestive organelles (e.g. lysosomes) for degradation and
cytoplasmic storage within endocytic compartments (Doherty and McMahon 2009).
Additionally, endocytosis can occur by both clathrin-mediated and clathrin-independent
processes, the former which is associated with the cytosolic protein clathrin, a large
protein that assists in the formation of clathrin-coated pits on the inner surface of the
plasma membrane. Endocytosis is generally subdivided into three groups: pinocytosis,
receptor-mediated endocytosis, and phagocytosis (Decuzzi and Ferarri 2007), although
disagreement exists among scientists about how endocytosis should be classified and
some literature describes receptor-mediated endocytosis as a type of pinocytosis and
considers phagocytosis as a separate cellular process altogether. Almost all cells of the
body are capable of pinocytosis (also known as fluid endocytosis), an important cellular
function by which cells engulf a portion of the extracellular fluid and all suspended
and/or dissolved solutes, macromolecules, and small particulate matter. Unlike receptormediated endocytosis (RME), where ingestion of certain substances (e.g. cell surface
proteins, viruses, etc.) is triggered by a ligand binding to its specific cell receptor,
pinocytosis is non-specific as whatever substances/solutes are found within the area of
invagination are brought into the cell from the extracellular environment (Lodish, Beck,
Zipurksy, Matsudaira, Baltimore and Darnell 2000). RME is a highly complex and tightly
regulated process used by most cells for the internalization of extracellular molecules
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(e.g. proteins, viruses, transmembrane receptors, ion channels, etc.) in response to ligands
binding to complementary cell-surface receptors and allows for precise regulation of the
interactions between the cell and its environment. For example, regulation of cell
sensitivity to specific extracellular ligand-mediated cues is achieved by RME, resulting in
removal of certain transmembrane receptors so they are no longer available for these
interactions (Doherty and McMahon 2009). Subsequent to ligand-receptor binding,
clathrin-pits invaginate into the cell and bud off to yield ligand-receptor complexes in
clathrin-coated vesicles (CCVs), and once transported from the cell membrane, are
uncoated and the contents of the vesicles delivered to their target locations (Decuzzi and
Ferrari 2008).
Phagocytosis is a special type of actin-dependent endocytosis used by specific
immune cells, namely neutrophils, DC and monocytes/macrophages, as a major immune
defense mechanism for the envelopment and internalization of large foreign particulates
(usually >250 nm in size), bacteria, dead and/or dying cells, etc. (May and Machesky
2001). Phagocytosis requires recognition and binding of the material to specific plasma
membrane receptors (e.g. Fc receptors, mannose receptors, scavenger receptors, etc.)
capable of triggering intracellular uptake (usually by formation of F-actin driven
pseudopods) of the membrane bound particle in vesicles called phagosomes. Subsequent
to ingestion, phagosomes typically fuse with endosomes and/or lysosomes, exposing their
contents to hydrolytic enzymes for digestion and intracellular processing of the material
results in cell surface Ag-presentation (expression of a conserved protein sequence) on
the phagocyte surface (May and Machesky 2001).
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T Cells and Their Role in the Immune Response
T cells and B cells belong to a specific group of white blood cells called
lymphocytes (Beilhack and Rockson 2003). T cells are named after the thymus gland
which is the tissue in which they mature, and it is here that T cells migrate (after
originating in the bone marrow) and begin to express an Ag-specific binding receptor on
their surface called the T cell receptor (TCR) (Medema and Borst 1999). T cells play an
integral role in both the innate and mammalian acquired immune responses by
coordinating and activating immune cells from both arms of the immune system against a
specific Ag and have direct, Ag-specific cytotoxic killing abilities. T cells are unique in
that they almost only recognize and become activated by Ag presented in the context of a
specific type of cell-membrane molecule, called a major histocompatibility complex
(MHC) (Hummell 1994). Once activated, T cells are responsible for a myriad of activities
which include mounting a specific defense against the foreign pathogens, direct killing of
virally infected cells or tumor cells, and regulation of the T cell mediated response
(Beilhack and Rockson 2003). T cells are divided into two subpopulations: T helper cells
(TH) and cytotoxic T cells (Tc) (Huston 1997). TH cells express a CD4 receptor on their
surface and are thus named CD4+ T cells, while TC cells express a CD8 receptor and are
named CD8+ T cells. CD4+ TH cells recognize Ag presented in the context of MHC II, a
protein found on the surface of APC cells, while CD8+ TC cells recognize Ag presented
by MHC I, a protein found on all nucleated cells (Medema and Borst 1999). TC cells
possess direct cytotoxic capabilities toward virally infected cells and cancer/tumor cells
and are the cells involved in tissue rejection after transplantation (Behrens et al. 2004).
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Additionally, all T cells are defined as either memory T cells or naïve T cells, a
classification based on prior exposure to a specific Ag (Surh and Sprent 2008).

CD4+ T Helper (TH) Cells
T helper cells (TH) comprise a subset of T lymphocytes responsible for
orchestrating the immune response (Cohn 2005) and are also referred to as CD4+ T cells
due to the expression of a membrane glycoprotein molecule found on their surface called
the cluster of differentiation (CD) type 4 (Schepers, Arens and Schumascher 2005).
Unlike other types of immune cells, TH cells are unique in that they do not phagocytose
and/or have any direct cytotoxic abilities (Behrens et al. 2004) but instead are capable of
recognizing Ag presented in the context of MHC class II proteins found on the surface of
APCs, namely B cells, DCs and macrophages/monocytes (Krogsgaard and Davis 2005).
Once TH cells bind to the Ag-MHC II complex, they release numerous cytokines which
bind to specific receptors located on the membranes of various cell types, and activate
and direct immune cell activity involved in inflammation and pathogen elimination
(Wieder, Braumuller, Kneilling, Pichler and Rocken 2008). In addition to activating a
host of different immune cells, cytokines direct the differentiation of T helper cells into
two different subsets, type 1 (Th1) and type 2 (Th2) (Fishman and Perelson 1999).

Th1 Versus Th2
Activated TH cells secrete various cytokines which result in the activation and
proliferation of other immune cells and initiate differentiation of T helper cells into two
classes, Th1 and Th2 (Bowers 2006b). Th1 and Th2 differ in the cytokines they secrete,
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which impacts the type of immune response produced, either a humoral, B-cell/antibodybased response, or a cellular, inflammatory-based response (Bowers 2006b). Th1
induction occurs in the presence of IL-2 and TNF-, cytokines secreted mainly from
macrophages/monocytes and DC (Fishman and Perelson 1999) and stimulate cells
involved in the inflammatory response (e.g. macrophages/monocytes, DC and NK) to
proliferate and secrete pro-inflammatory cytokines such as IL-12, IFN-gamma, etc. (Guo
et al. 2004) At the same time, Th1 cells inhibit the production of IL-4, a major cytokine
involved in promoting Th2 differentiation, thereby preserving and maintaining the Th1
response (Fishman and Perelson 1999).
The primary function of Th2 cells is to stimulate B cell proliferation and induce
B-cell antibody class switching resulting in increased antibody production against a
particular pathogen (Liberman, Refojo and Arzt 2003; Kondo 2003). The cytokines
secreted by Th2 cells (e.g. IL-4, IL-5, IL-6, IL-10 and IL-13) serve to activate B cells and
maintain the Th2 response by inhibition of cytokines critical for Th1 differentiation and
result in Ag elimination and clearance of invading pathogens from the host (Sallusto,
Palermo, Hoy and Lanzavecchia 1999; Fishman and Perelson 1999).

Memory Versus Naïve T Cells
T cells clones of antigenically-stimulated cells are called memory T cells, while T
cells that have not yet encountered peripheral cognate Ag are called naïve T cells (Surh
and Sprent 2008) and these T cell subsets are distinguished from each other based on
their response to Ag and expression of specific cell surface markers. Memory T cells,
characterized by the expression of the cell surface marker CD45RO (CD45RO +), persist
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after Ag exposure and remain dormant and inactive until a secondary encounter takes
place (Surh and Sprent 2008). Unlike memory T cells, naïve T cells (Th0) have not
encountered cognate Ag, and are non-prolific quiescent cells characterized by the
expression of the cell-surface marker CD45RA (CD45RA+ cells) (Zimmermann, PrevostBlondel, Blaser and Pircher 1999). Naïve T cells circulate throughout the body in a state
of homeostasis until encounter with novel Ag, and upon activation adopt an activated or
―memory‖ phenotype. The process of aging skews the memory to naive T cell ratio in
favor of memory cells, which is partly responsible for the reduced ability of geriatric
populations to effectively fight infection and disease (Surh and Sprent 2008). Both
memory and naïve T cells are critical elements of the immune response; memory T cells
allow for a fast response to previously encountered Ag, while naïve T cells are slower to
respond, but enable the host to fight novel pathogens.

T Cell Activation
All mature T cells express the T cell receptor (TCR) on their surface, which is
required for the ability of T cells to recognize and respond to Ag presented by APCs
(Rojo, Bello and Portoles 2008). Each TCR is composed of two transmembrane
polypeptides,  and  or and , with  bearing T cells being the more common type
(Modlin and Sieling 2005). Each TCR subunit has one variable and one constant domain,
and at the end of each TCR are hypervariable loops that recognize Ag presented by MHC
(Godfrey, Rossjohn and McCluskey 2008). Additionally, each TCR molecule is
associated with a molecule called CD3, a complex critical for T cell signal transduction,
made up of five transmembrane polypeptides (, , , , and ) which come together to
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form three dimers (, , and or (Rojo et al. 2008). A correctly assembled TCRCD3 complex is essential for T cell activation since the TCR is necessary for recognition
of Ag (Feito, Jimenez-Perianez, Ojeda, Sanchez, Portoles and Rojo 2002). TCRs are
capable of distinguishing self from non-self through the recognition of both endogenous
(i.e. tumor cells and virally infected cells) and exogenous (i.e. bacteria) foreign
molecules. Upon pathogen recognition, APCs engulf and digest the foreign material into
smaller peptides which are expressed on the surface of the APC in the context of a MHC
molecule, and circulating T cells are able to recognize and bind to foreign peptide/MHC
complexes, resulting in T cell activation and subsequent pathogen clearance (Lindquist
and Schraven 2006).
CD28 is a surface molecule constitutively expressed on 80% of all CD4+ T cells
and is a co-stimulatory signal for further activation of T cells (Blair et al. 1997). CD28 is
comprised of disulfide-linked homodimeric glycoproteins, although some studies have
demonstrated the ability of CD28 to function in its monomer form as well (Bour-Jordan
and Blueston 2002). CD28 binds to the B7 protein expressed on the surface of activated
B cells, monocytes and T cells (Lenschow, Walunas and Bluestone 1996). The CD28/B7
pathway plays a major role in T cell activation, especially when activated by low Ag
concentrations or weak Ag as binding of the TCR/CD3 complex to a specific
peptide/MHC complex lowers the activation threshold required for T cell activation
(Bour-Jordan and Blueston 2002). Activation by CD3 alone requires the cross linking of
approximately 8000 TCRs, as opposed to activation by CD3/CD28, which requires the
cross-linking of approximately 1000 TCRs (Blair et al. 1997). The CD28/B7 costimulatory signaling pathway plays other important roles in T cell activation, such as
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stabilization of IL-2 mRNA (critical for T cell growth), increased expression of Bcl-XL
(an anti-apoptotic protein that promotes cell survival), and in the early development and
differentiation of Th1 and Th2 cells (Bour-Jordan and Blueston 2002; Lenschow et al.
1996).

B Cells and Their Role in the Immune Response
B cells and T cells fall in the class of immune cells known as lymphocytes which
are the principal cell types involved in the adaptive immune response. B cells make up
approximately 10% of the immune cell population, and can be identified by cell surface
expression of the CD19 marker (Goldsby, Kindt, Osborne and Kirby 2003). The primary
function of B cells is the production of antibodies (Ab) which are Ag-specific
immunoglobulins whose role is to immobilize and target foreign, pathogenic entities for
destruction (Bowers 2006a). Unlike T cells, which only recognize Ag presented by an
MHC molecule, B cells are able to recognize soluble Ag in its cognate native form
(Chaplin 2006) and are a type of APC whose principal function is to activate immune
cells against a specific Ag and mount an Ag-specific immune response (Alam 1998).
There are two ways in which B cells can be activated to produce Ab, the first type
is T cell-independent and occurs when the B cell receptor (BCR) recognizes and binds to
either soluble Ag circulating in the blood or bound Ag presented in the context of an
MHC molecule on immune cells (e.g. macrophages/monocytes), and the second type is T
cell dependent and occurs when a B cell recognizes and binds to a T H cell (specifically a
Th2 cell) previously activated or ―primed‖ by Ag (Goldsby et al. 2003). The result of B
cell activation is rapid proliferation of B cells, increased Ab production against the
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specific Ag, and cytokine induction in order to further stimulate other B cells and
activate other immune cells (Beilhack and Rockson 2003).

Natural Killer (NK) Cells and Their Role in the Immune Response
Natural killer (NK) cells are large, granular, cytotoxic lymphocytes capable of
detecting and eliminating a wide range of tumor cells and, to some extent, virally infected
cells (Parham 2005). NK cells make up 2% of the immune cell population (5-10% of
all lymphocytes), and play a critical role in the innate immune response (Alam 1998). NK
cells express several cell surface markers (CD16, CD56, Fc receptors, etc.) integral for
proper NK cell functioning which involves the release of cytotoxic molecules called
perforin and granzyme (a type of protease). In response to encounter with a virallyinfected or cancer cell, NK cells release these cytotoxic molecules and perforin proteins
form pore-like structures in the membrane of the target cell. Granzymes and associated
molecules are then able to enter and induce cell death by both apoptotic and necrotic
processes (Caligiuri 2008). The mechanisms by which NK cells identify potential target
cells involve the ability of NK cells to recognize cellular abnormalities, specifically a
reduction in MHC I surface expression (seen in many cancer and virally-infected cells),
and the Fc region of specific Ab directed against tumor and viral Ag found on the surface
of aberrant target cells (called cell-mediated cytotoxicity) (Middleton, Curran and
Maxwell 2002). In addition to direct destruction of mutated cells by granzymes and
perforin, activated NK cells secrete cytokines (e.g. IFN- and TNF-α) involved in
activating other types of immune cells (Le Page, Genin, Baines and Hiscott 2000).
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Monocytes and Their Role in the Immune Response
Monocytes are mononuclear cells responsible for the non-Ag specific recognition
and elimination of foreign, potentially pathogenic entities (e.g. bacteria, large particulate
matter, cellular debris, etc.) by a highly metabolic process known as phagocytosis
(Dobrovolskaia and McNeil 2007), and play an important role in the innate immune
defense, inflammation and tissue remodeling (Volk, Reinke and Docke 1999).
Phagocytosis results in the containment and destruction of pathogenic entities by
enzymatic digestion and ROS production, and subsequent Ag-presentation is critical for
immune cell activation (Dobrovolskaia and McNeil 2007). Monocytes make up 3-8% of
circulating leukocytes and two main subsets of monocytes have been identified based on
differences in phenotype and function (Uthaisangsook et al. 2002). Classical monocytes
are characterized by high levels of CD14 surface expression (called CD14 ++), and release
specific cytokines (e.g. IFN-α, TNF-α, IL-1, IL-6, etc.) in response to encounter with Ag.
These cytokines serve to activate other immune cells and initiate differentiation of
CD14++ monocytes into pro-inflammatory CD14+CD16+ monocytes (Le Page et al.
2000). CD14+CD16+ non-classical monocytes (derived from CD14++ monocytes) are
specifically associated with inflammation, exhibit increased TNF-α secretion, and upon
stimulation and activation, rapidly proliferate and migrate from the blood to the site of
assault where they differentiate into tissue-specific macrophages and DC for engulfment
of foreign material (Mayer 2006; Ziegler-Heitbrock 2007). Phagocytosis is initiated by
both receptor-and non-receptor mediated processes, the former involving recognition of
pathogens via specific cell surface receptors such as mannose-receptors, scavengerreceptors and Fc receptors. Mannose receptors allow for recognition and phagocytosis of
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bacteria by binding terminal mannose and fucose residues of glycoproteins and
glycolipids present in microbial cell walls, a feature that distinguishes bacteria from
mammalian cells whose glycoproteins and glycolipids contain terminal sialic acid or Nacetylgalactosamine residues instead of mannose and fucose (Kantari, Pederzoli-Ribeil
and Witko-Sarsat 2008). Similar to mannose-receptors, scavenger-receptors are able to
detect various microbes as well as low-density lipoprotein (LDL) particles. Monocytes
also recognize pathogens via Fc receptors which bind the Fc region of Ab attached to
infected cells and microorganisms (called opsonization) to stimulate phagocytosis in a
process known as Ab-dependent phagocytosis (Kantari et al. 2008). In addition to Ag
processing and presentation for immune cell activation, monocytes are capable of
producing high levels of reactive oxygen species (ROS) for intracellular destruction of
engulfed pathogenic material located within phagosomes. Fusion of phagosomes with
digestive enzyme containing lysosomes initiates assemblage of NADPH oxidase subunits
which catalyze the synthesis of superoxide anion (O2-) in a process called the respiratory
burst. Conversion of O2- to hydrogen peroxide (H2O2) by superoxide dismutase (SOD)
results in pathogen killing and the importance of this mechanism is illustrated in a genetic
condition known as chronic granulomatous disease (CGD), a genetic condition in which
the gene encoding NADPH oxidase is defective or missing, resulting in chronic bacterial
infections (Ziegler-Heitbrock 2007).

Inflammation and Immune System Activation
Inflammation is the complex sequence of biological events due to tissue damage
caused by a wound, invading pathogens, or other foreign material and is characterized by
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redness, heat, swelling and pain (Martin and Leibovich 2005). The symptoms associated
with inflammation are due to three major inflammatory responses, vasodilation, increased
capillary permeability, and influx of phagocytes (Martin and Leibovich 2005). These
responses, which are initiated by a complex series of events involving the secretion of
various cytokines and chemokines, have evolved to allow expedient immune cell access
to the area of infection for intended clearance of the pathogen (Mackay 2001).
Cytokines are soluble low molecular weight signaling molecules (proteins,
peptides or glycoproteins) secreted by cells for the purposes of cell-to-cell
communication and immune system regulation (Bellanti, Kadlec and Escobar-Gutierrez
1994). Although not strictly confined to the immune system, cytokines are essential to the
development and modulation of both the innate and adaptive immune responses. For
example, in response to encountering a pathogen, cells of the innate immune system
secrete specific cytokines which act to activate and recruit other immune cells to help
fight the foreign pathogen (Mulloy and Rider 2006). Once secreted from a cell, cytokines
bind to specific cell-surface receptors located on adjacent cells (paracrine), cells in a
distant location (endocrine), or even the secreting cell itself (autocrine) (Mackay 2001).
Binding of a cytokine to its ligand produces intracellular cell-signaling cascades which
result in the up- or down-regulation of genes, transcription factors, and release or
inhibition of other cytokines and/or cytokine receptors (Mulloy and Rider 2006). The
effects produced by a particular cytokine depends on many factors, such as cell type,
cytokine concentration, the absence of specific receptors for that particular cytokine and
the downstream signaling events that occur due to receptor binding (Alfano and Poli
2005).

28
Cytokines play an integral role in inflammation and stimulating immune cell
activation to fight infection. Although the inflammatory response is designed as a
protective measure against exposure to foreign, potentially disease causing entities,
unresolved inflammation (often due to exposure to innocuous substances) can have
serious and often fatal consequences and is an important consideration when designing
new therapeutic treatments (Uthaisangsook et al. 2002). Manipulating the inflammatory
response so that immune cell activation against a specific entity is achieved, is one way in
which more targeted therapeutic treatments for disease may be accomplished. In
summary, cytokines are critical in directing and coordinating the immune response and
three important immunomodulating cytokines described in this research are IFN-, TNFα and IL-12.

IFN-
Interferon- (IFN- , originally called ―macrophage-activating factor‖) is an acidlabile, soluble cytokine that is biologically active in its dimerized form, with each
monomer being comprised of six α-helices (Schroder, Hertzog, Ravasi and Hume 2004).
IFN- is secreted by NK cells, CD4+ TH cells (specifically Th1 cells), CD8+ TC cells and
DC and has anti-viral, immunoregulatory and anti-tumor properties (Schroder et al.
2004). IFN- binds to receptors found on the surfaces of almost all cells of the body
(with receptor number varying by cell type) to produce a variety of different
physiological and cellular responses which include, but are not limited to, activating
macrophages and monocytes to increase Ag presentation and lysozyme activity,
suppression of the Th2 response and promotion of Th1 response, increases in MHC I
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expression, promotion of leukocyte migration by increasing adhesion and binding,
activation of NK cells, and up regulation of various transcription factors involved in
immunomodulation (Tau et al. 2000).

TNF-α
Tumor necrosis factor-α (TNF-α) is a trimeric, 17 kilo-Dalton (kd) (it is 17 kD in
its secreted form, and 27 kD in its transmembrane noncleaved form) inflammatory
cytokine with pleiotrophic effects (Wajant, Pfizenmaier and Scheurich 2003). For
example, the effects of TNF-α can be both growth stimulatory, as seen in the case of
neutrophil stimulation during inflammation, and growth inhibitory, as seen in neutrophil
apoptosis upon TNF- α binding to the TNF-R55 receptor (Gaur and Aggarwal 2003).
TNF-α is produced and secreted by a variety of different cell types including neutrophils,
T cells, NK cells, and macrophages/monocytes, and receptors for TNF-α are found on
most cells of the body (Wajant et al. 2003). TNF-α is involved in many different
biological processes including maintenance of circadian rhythms, replacement and
remodeling of injured tissues via fibroblast stimulation, fighting pathogenic infections,
and inducing cell death of cancer-causing cells (Locksley, Killeen and Lenardo 2001).
However, over-abundant and chronic exposure to TNF-α has been shown to have
detrimental effects for host health such as pernicious vascular permeability (as seen in
septic shock), over-activation of immune cells leading to pathologic clot formation, and
has been shown to play an important role in carcinogenesis (Mocellin and Nitti 2008).
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IL-12
Interleukin 12 (IL-12 is a heterodimeric, cytokine composed of four alpha helices
and encoded by two separate genes, IL-12A (p35) and IL-12B (p40) secreted primarily
by B cells, DC, macrophages/monocytes and to a lesser extent, T cells (Maranda and
Robak 1998). IL-12 is involved in a variety of different functions including stimulation of
T cell differentiation (Th1) and proliferation, IFN- and TNF-α induction by T cells and
NK cells, and reduction of IL-4 mediated suppression of IFN- (Goriely and Goldman
2007). Additionally, IL-12 has clinical relevancy and is being investigated as a potential
adjuvant for IL-2 adoptive lymphokine-activated killer cell (LAK cell) immunotherapy as
it reduces the doses of IL-2 required and thus decreases toxicity associated with IL-2
treatment (Lissoni, Pittalis, Roselli, Rovelli and Vigano 1996).
Although too much inflammation can be detrimental to the integrity of an
organism, some inflammation can be beneficial in stimulating an immune response
against disease causing cells. For example, inflammation stimulates immune cells such as
monocytes, neutrophils, etc., to produce ROS which induces cytotoxicity in pathogens or
infected cells and results in robust immune responses against invading entities
(Uthaisangsook et al. 2002).

Reactive Oxygen Species (ROS)
Reactive oxygen species (ROS) are molecules and ions containing unpaired
valence shell electrons and constitute a type of free radical specifically involving oxygen
(Bergamini, Gambetti, Dondi and Cervellati 2004). The unpaired valence shell electrons
make ROS highly reactive, and although ROS play an important role in cell signaling,
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excess ROS (called oxidative stress) can result in significant cellular damage which can
ultimately lead to cellular demise by both necrotic and apoptotic processes (Davies
2000). Types of ROS formed as a result of the sequential reduction of molecular oxygen
include superoxide radical (∙O2-)superoxide anion (O2-), hydrogen peroxide (H2O2) and
the hydroxyl radical (OH) (Bergamini et al. 2004).
Sources of ROS are both exogenous and endogenous in nature. Exogenous
mediators of intracellular ROS production such as UV light and ionizing radiation exert
their deleterious effects by damaging DNA, proteins and lipids resulting in cell damage,
cell death and in some instances the creation of malignant cells (if genes responsible for
controlling cell growth and replication are damaged). Although excessive ROS
production can result in cell damage and death, ROS play a critical role in many normal
cellular functions. For example, ROS can be formed as a necessary intermediate in
various enzyme reactions and WBC (e.g. neutrophils, macrophages/monocytes, etc.)
utilization of ROS for host defense mechanisms and cellular communication (e.g. nitric
oxide) (Valko, Leibfritz, Moncol, Cronin, Mazur and Telser 2007).
A major endogenous source of ROS are mitochondria, which produce H2O2 from
∙O2- as a natural by-product of ATP production as oxygen is reduced along the electron
transport chain (Bergamini et al. 2004). This can damage cells both directly and
indirectly as H2O2 interacts with Fe2+ or other catalytic metals (a process known as the
Fenton reaction) and is converted into the highly destructive OH radical (Bacic,
Spasojevic, Secerov and Mojovic 2008). The metabolism and detoxification of drugs,
pollutants and ingested particular matter (collectively called xenobiotics) can also serve
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as a major endogenous source of free radicals which is important to consider when new
drugs and novel materials are being evaluated for utilization (Valko et al. 2007).
Cellular processes, in the form of intracellular enzymes, have evolved to
neutralize the potentially harmful effects of ROS produced in physiologically moderate
amounts. These enzymes include superoxide dismutase, catalase, and the glutathione
enzymes (e.g. glutathione-peroxidase, glutathione-reductase and S-glutathione
transferase) (Willcox, Ash and Catignani 2004). Superoxide dismutase is found in both
the mitochondrial matrix and cytoplasm and catalyzes the formation of H2O2, O2 and
water from the potent highly damaging superoxide radicals (O2-) produced in the
electron transport chain. Under conditions in which superoxide dismutase becomes
overwhelmed (e.g. during oxidative stress), excessive amounts of H2O2 are produced
resulting in the formation of OH via the Fenton reaction (Benzie 2000).
Catalase is localized in digestive organelles known as peroxisomes and exerts its
antioxidant effects by reacting with H2O2 to catalyze the formation of O2 and water
(Djordjevic 2004). Glutathione is an important antioxidant tri-peptide synthesized from
the amino acids L- cysteine, L-glutamic acid and glycine, and in its reduced state
participates in conjugation reactions to remove various toxic metabolites and donates
electrons to unstable ROS molecules (Devasagayam, Tilak, Boloor, Sane, Ghaskadbi and
Lele 2004).
During oxidative stress glutathione precursors become depleted and glutathione
production is insufficient in neutralizing the ROS generated. To combat diminished
glutathione levels, exogenous supplemental cysteine rich compounds, such as N-acetyl
cysteine (NAC) can be used to restore glutathione precursor reserves for conversion by
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specific enzymes and replenishment of glutathione stores (Townsend, Tew and Tapiero
2003).
Excessive ROS production has been implicated in a variety of different human
diseases such as cancer, atherosclerosis and neurodegenerative disorders, and exerts its
damaging effects by reacting with cellular components, causing cell death by both
necrotic and apoptotic processes.

Cell Death: Apoptosis and Necrosis
Cell death can occur by two different mechanisms, apoptosis and necrosis.
Apoptosis is a type of programmed cell death or ―cell suicide‖ involving a predictable
series of biochemical events and morphological changes such as decreased cell volume,
modification of the cytoskeleton resulting in membrane blebbing, chromatin
condensation and DNA fragmentation (Winoto 1997). Subsequent to these changes, the
apoptotic cell breaks into small membrane-bound particles called apoptotic bodies which
signal phagocytic immune cells (e.g. macrophages and monocytes) to engulf the
apoptotic bodies, avoiding the release of cellular contents into the surrounding tissue and
induction of a local inflammatory response (Elmore 2007). Unlike apoptosis, necrosis is
not programmed by the cell, but is cell death due to overwhelming injury from which the
cell is unable to recover. In necrosis, the damage incurred causes the cell to swell and
burst, spilling its cellular contents into the surrounding environment and the dispersed
cellular debris triggers an inflammatory response in an effort to clear the debris and
remove the offending stimulus (Proskuryakov, Gabai, Konoplyannikov, Zamulaeva and
Kolesnikova 2005). Apoptosis is essential in maintaining homeostasis and host health and
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is critical for cell differentiation during embryogenesis. Additionally, apoptosis is
responsible for sustaining a stable number of cells in the body, controlling the growth of
aberrant mutated cells and is one of the mechanisms by which immune cells, namely NK
and TC cells, induce cytotoxicity. Also, the absence of apoptosis (due to genetic
mutations, for example) can have dire consequences for the organism resulting in the
development of diseases such as cancer and autoimmunity (Kam and Ferch 2000).

In conclusion, the utilization of NP (specifically metal oxide NP) is everincreasing, and NP are already found in many different commercial products. Due to their
unique properties, it is essential to elucidate the effects and mechanisms of NP-biological
interactions and investigate the biomedical potential of different types of particles on
various cell types and systems. Evaluating parameters influencing NP toxicity ensures the
safe use of NP for various industrial applications and may allow for the creation of new
and improved therapeutic treatments for disease. Our immediate goal is to examine the
differential toxic effects of metal oxide NP, specifically ZnO NP, on primary human
immune cells. The main hypothesis of this research is that ZnO NP toxicity is dependent
on various parameters including cell type, NP size, and cell-activation state. Additionally,
our research evaluated specific mechanisms of toxicity, cell death and the inflammatory
potential of ZnO NP in immune cells. Exploitation of these observations may enable the
development of novel treatments for disease, which is the long term goal of our research.
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EXPERIMENTAL PROCEDURES

Preparation and Characterization of ZnO NP
ZnO NP utilized in all experiments were synthesized in diethylene glycol (DEG)
via forced hydrolysis of zinc acetate (Reddy et al. 2007). In brief, zinc acetate was
dissolved in DEG, and nanopure water was added under magnetic stirring. Subsequently,
the system was heated at 160 ºC under reflux for 90 min. After cooling, the resulting
product was removed from DEG via centrifugation and washed with ethanol several
times before drying for 24 h at 50 °C, resulting in a powder sample. The sample crystal
phase, crystallite size and morphology were characterized via x-ray diffraction (XRD),
and transmission electron microscopy (TEM) (Hanley et al. 2008; Reddy et al. 2007).
The NP powder was weighed and reconstituted in phosphate buffered saline (PBS)
solution to the desired stock concentration. After reconstitution, NP were sonicated for 10
min and immediately vortexed prior to addition to cell culture samples. For all
experiments, except for those directly comparing effects of NP size on cell viability and
ROS production, 8 or 13 nm ZnO NP were used as specified.
Different sized ZnO NP were synthesized as described above and sizes altered by
modifying the hydrolysis molar ratio of water to zinc acetate with ratios of 2.4, 6.1, 12.2,
and 36.6 yielding NP with average diameters of 4 nm, 8 nm, 13 nm, and 20 nm,
respectively. The corresponding particle size for all four NP sizes analyzed reveals a
narrow size distribution and XRD patterns indicate all of the ZnO samples are well
indexed to pure wurtzite crystallite phase of ZnO. Furthermore, the average crystallite
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sizes estimated using the peak widths (full width at half maximum) of the XRD patterns
agree well with TEM results.

Preparation of FITC-Doped ZnO NP
FITC encapsulated ZnO (FITC-ZnO) particles were synthesized by forced
hydrolysis and condensation of FITC-binding silane and silicate to obtain the FITC-SiO2
core (Burns, Ow and Weisner 2006), and the ZnO surface layer formed using zinc salt
(Wang et al. 2009). The core-shell structure of the ~200 nm sized FITC-ZnO particles
and the presence of a surface layer of 13 nm sized ZnO NP were confirmed using TEM,
XRD and x-ray photoelectron spectroscopy (XPS) studies, and fluorescence properties
were investigated using photoluminescence spectroscopy and flow cytometry (Wang et
al. 2009).

Preparation of SnO2 and CeO2 NP
SnO2 NP were synthesized by our collaborators using methodologies nearly
identical to those described for ZnO NP preparation (Reddy et al. 2007). Briefly, SnO2
NP were synthesized in diethylene glycol (DEG) via forced hydrolysis of tin chloride and
the resulting product was removed from DEG via centrifugation and washed with ethanol
several times before drying for 24 h at 50 °C, resulting in a powder sample of 4-8 nm
sized NP. CeO2 NP were synthesized from cerium nitrate by sol-gel preparation resulting
in a 9 nm NP powder sample. For use in mammalian cell cultures, NP were weighed
and reconstituted in phosphate buffered saline (PBS) solution to the desired stock
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concentration, sonicated for 10 min, and immediately vortexed prior to addition to cell
samples.

Immune Cell Isolation and Cell Culture
Isolation of Peripheral Blood Mononuclear Cells (PBMC)
For isolation of PBMC (peripheral blood mononuclear cells) and immune cell
subsets, written informed consent was obtained from all blood donors and the University
Institutional Review Board approved this study. PBMC were obtained via FicollHypaque (Histopaque-1077, Sigma, St Louis, MO) gradient centrifugation using
heparinized phlebotomy samples (Coligan 1995). After removal of the leukocyte layer,
cells were washed three times with Hank’s buffer (Sigma, St. Louis, MO) and
resuspended to a final concentration of 1-2 x 106 cells/mL in RPMI-1640 (Sigma)
containing 10% fetal bovine serum (FBS) and cultured at 37 C and 5% CO2.

Primary CD4+ T Cell Isolation
After isolation of human PBMC, CD4+ T cells were purified using negative
immunomagnetic selection per manufacturer’s instructions using a cocktail of antibodies
against CD8, CD14, CD16, CD19, CD56, and glycophorin A (StemCell Technologies,
Vancouver, BC) with collection of unlabeled T cells (typically >97% CD4+ and >90%
viable as assessed by flow cytometry). Purified CD4+ cells were cultured in RPMI/10%
FBS and suspended at a final concentration of 1-2 x 106 cells/mL.
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Primary CD14+ Monocyte Isolation
PBMCs were obtained by Ficoll-Hypaque density centrifugation as described
above and CD14+ cells isolated from the mixed cell suspension. Negative
immunomagnetic selection was performed according to the manufacturer’s protocol
using a cocktail of antibodies directed against CD2, CD3, CD16, CD19, CD20, CD56,
CD66b, CD123, glycophorin A (StemCell Technologies, Vancouver, BC). For optimal
cell recovery, PBMCs were first blocked with anti-human CD32 (Fc RII) blocker
reagent before labeling with the antibody cocktail and running through the column.
Collection of CD14+ monocytes was typically >97% viable as assessed by flow
cytometry. Purified monocytes were then cultured in RPMI/10% FBS at 5 x 105 cells/mL
in 200 L total volume in 96-well microtiter plates at 37 C and 5% CO2.

Jurkat Lymphoma, Hut-78 Leukemic, and U937 Monocytic Cancer Cell Lines
The Jurkat lymphoma T cell, Hut-78 leukemic T cell and U937 monocytic cancer
cell lines (ATTC, Rockville, MD) were cultured in RPMI 1640 supplemented with 10%
FBS (Jurkat) or 20% FBS (U937) and 2 mM L-glutamine, 1.5g/L sodium bicarbonate,
4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate. Cells were maintained in
log phase at 37 C and 5% CO2 and seeded at 5 x 105 cells/well in 96-well plates for
individual experiments.

Antibodies (Ab) and Flow Cytometry
Flow cytometric analyses were performed using a 4-color Epics XL flow
cytometer (Beckman Coulter, Fullerton, CA). Immunofluorescent staining was
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accomplished by harvesting cells plated at a concentration of 1 x 10 6 cells/mL into FACS
buffer and centrifuging for 10 min at 2000 rpm to pellet cells. After supernatant removal,
cells were resuspended in FACS buffer and stained with fluorescently labeled Ab
(Beckman Coulter, Fullerton, CA). Appropriate concentrations of each Ab were
determined by titration for optimal staining prior to experimental use. Cells were
incubated with the appropriate fluorescent Ab for 30 min at 4C, washed two times,
harvested into FACS buffer and immediately analyzed. Ten thousand events gated on the
parameters of size (forward scatter - FS) and granularity (side scatter - SSC) were
analyzed, and expression of the percentage of positively staining cells or the mean
fluorescence intensity (MFI) determined by comparisons to isotype controls. In PBMC
cultures, individual cell types were distinguished from one another based on differential
Ab staining and FS and SSC properties. T cells were defined as CD3+; TH defined as
CD3+,CD4+; naïve T cells defined as CD3+,CD45RA+; memory T cells defined as CD3+,
CD45RO; B cells defined as CD19+,CD3-; NK cells defined as CD56+,CD16+, CD3-, or
CD56+, CD3-; and monocytes defined as CD14+,CD3-. To prevent indiscriminate Ab
staining of monocytes via Fc receptors, 100 L of heat-inactivated human AB serum was
added to experimental samples immediately prior to staining.

T Cell Activation and Culture Conditions
Purified CD4+ cells were cultured in RPMI/10% FCS at 1 x 106 cells/mL in 200
μL total volume and activated using immobilized CD3 Ab (1.0 g/well of clone OKT3,
ATCC, Rockville, MD) +/- CD28 Ab (0.25 g/well of clone CD28.2 (PharMingen, San
Diego, CA) in 96-well tissue culture plates. Cultures were treated with freshly prepared
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and sonicated NP, or left untreated for varying lengths of time and analyzed using flow
cytometry and a microplate reader. T cell activation was verified by detecting an increase
in membrane CD40L protein expression using flow cytometry.

Cell Viability Assays
Flow Cytometric Analysis of Immune Cell Viability
To assess the effect of ZnO NP on PBMC and isolated immune cell viability, two
different flow cytometric assays were employed. In the first assay, cells identified were
stained and identified using fluorescently labeled Ab and viability determined by staining
with 50 g/mL of propidium iodide (PI), a fluorogenic dye used to monitor losses in cell
membrane integrity, for 10 min prior to analysis. Fluorescent CountBright ® counting
beads (Invitrogen, Carlsbad, CA) were added to samples to enable determinations of
absolute cell numbers, and flow cytometry used to evaluate changes in PI staining and
quantify cell death. NP were excluded from the analysis based on absence of
fluorescence signal and light forward scatter (FS) and side scatter (SSC) characteristics.
In experiments testing the effects of micron-sized bulk ZnO on cell viability, purified
CD4+ T cells were left untreated or treated with various concentrations of commercially
available (Sigma Aldrich, St. Louis, MO) bulk ZnO powder or laboratory synthesized
ZnO NP resuspended in PBS, cultured for 20-24 h, and viability assessed using PI and
analyzed by flow cytometry. Identical conditions to those just described were used for
experiments testing the effects of SnO2 NP and CeO2 NP on T cell viability, except that
only one concentration (e.g. 10 mM) of either SnO2 NP or CeO2 NP was evaluated.
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A second viability assay, the LIVE/DEAD viability assay for mammalian cells
(Invitrogen, Eugene, OR) was used to verify results seen using PI. Per manufacturer’s
protocol for flow cytometry, purified CD4+ T cells were dually stained with two
fluorescently labeled probes that enable the simultaneous determination of live and dead
cells in a sample. Calcein AM was used to stain live cells as it fluoresces only when
cleaved by intracellular esterases, and EthD-1 was used to identify dead/dying cells as it
exclusively enters cells with disrupted cell membranes.

Flow Cytometric Analysis of Bacterial Viability
Two different strains of bacteria (E. coli and S. aureus) were provided by our
collaborator, Dr. Kevin Feris, for determination of bacterial cell viability. Bacterial
cultures (E.coli and S. aureus) were grown for 3 h in LB medium and subsequently
treated with ZnO NP resuspended in PBS. After 15 h of treatment, a two color live/dead
BacLight® bacterial viability kit (Molecular Probes, Carlsbad, CA) was used to determine
cell viability as analyzed by flow cytometry. The ratio of dead to live bacteria remaining
in the culture following NP exposure was determined by simultaneously staining with PI
and a green fluorescent dye, Syto9, that intensely stains cells with intact membranes and,
to a lesser extent, cells with damaged membranes. Populations of live (green) and dead
(red) bacteria were discriminated based on green and red fluorescence staining profiles
and changes in FS and SSC characteristics.
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Alamar Blue Viability Assay
The Alamar Blue viability assay, which utilizes the fluorogenic redox indicator
dye, Alamar Blue, was also used to evaluate NP-induced cytotoxicity. This dye becomes
fluorescent upon reduction by mitochondrial enzymes in metabolically active (live) cells.
Cells were seeded into 96-well plates at 5 x 105 cells/mL in a final volume of 200 L and
treated with ZnO NP for 18 h. Alamar Blue (20 L) was added to cultures for an
additional 6 h of culture for a total NP-exposure time of 24 h. A BioTek®
spectrophotometer was used with an excitation/emission at 530/590 nm to monitor and
record changes in fluorescence and viability was normalized to fluorescence values from
control wells.

Determination of IC50 Values for Immune Cells
To determine the concentration at which 50% of cells remain viable (IC 50),
experiments were performed testing the effects of varying concentrations of ZnO NP on
cell viability. To determine the IC50 values for purified T cell and monocytes, cells were
treated with varying concentrations of ZnO NP (1 mM, 5 mM and 10 mM for T cells and
0.0625 mM, 0.25 mM, 0.5 mM and 1 mM for monocytes) for 22-24 h and viability
assessed using the Alamar Blue assay. The program GraphPad Prism 5.0 was used to
calculate IC50 values for purified CD4+ T cells and CD14+ monocytes by plotting cell
viabilities against the logarithm of NP concentration and using a nonlinear regression
analysis to fit a variable slope dose-response curve. For cells found in mixed PBMC
cultures, cell types were identified using fluorescently labeled antibodies against specific
plasma membrane markers and viabilities determined by PI uptake and flow cytometry.
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To calculate IC50 values for these flow cytometric experiments, cell viabilities were
plotted against NP concentrations and a linear regression analysis used to determine IC 50
values.

Reactive Oxygen Species (ROS) Assays
ROS Detection
To assay for NP-induced ROS production in primary lymphocytes and
monocytes, cultures of mixed PBMC were obtained from whole blood treated with an
ammonium chloride lysing solution (1.5 M NH4Cl, 0.1 M NaHCO3, 0.01 EDTA) used to
lyse red blood cells and centrifuged for 10 min at 4C to remove erythrocytic debris.
PBMC were counted, resuspended in phenol red-free RPMI to a final concentration of 1
x 106 cells/mL and treated with 1 mM or 5 mM of ZnO NP (8 nm). To evaluate ROS
production, cells were loaded with 5 M of the oxidation-sensitive dye, 2’,7’dichlorofluorescein diacetate (DCFH-DA, Invitrogen, Carlsbad, CA) for 20 min prior to
analysis. The oxidation product of DCFH-DA has an excitation/emission maxima of
~495 nm/529, enabling detection both by using a microplate reader and flow cytometry
(Luo et al. 2002). In flow cytometric analyses, CD3+ lymphocytes and CD14+ monocytes
were identified based on FS and SSC gating and staining with fluorescently labeled Ab,
allowing for simultaneous cell identification and evaluation of ROS production.
Additionally, ROS production in PBMC cultures was measured after several different
NP-exposure times (6 h – 24 h) to assess the kinetics of NP-induced oxidative stress. To
compare NP-induced ROS in primary cells with cancer cells, Hut-78 T leukemic cells
were treated with ZnO NP and ROS measured using similar methodology as described
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for primary cells. As a positive control for ROS production in all cell types tested,
untreated (no NP) cells were loaded with DCFH-DA and activated with PMA (25 ng/mL)
for 1 h prior to analysis.
In parallel experiments investigating the effect of NP size on ROS production,
bulk cultures of PBMC were treated with various concentrations (5 mM and 10 mM) of
different sized ZnO NP (4, 13, and 20 nm), loaded with DCFH-DA and ROS production
analyzed using a fluorescent microplate reader as described by others (Hong and Liu
2004; Onaran, Sencan, Demirtas, Aydemir, Ulutin and Okutan 2008).

ROS Quenchers
To determine the role of ROS in NP-induced cell death, primary purified CD4+ T
cells and CD14+ monocytes were seeded in a 96-well plates at a concentration of 5 x 105
cells/mL and treated with the ROS scavenger, N-acetyl cysteine (NAC, Sigma Aldrich,
St. Louis, MO). NAC was made as a stock solution in sterile nanopure water and added
to cells at a final concentration of 5 mM. Cells were pretreated with NAC for 2 h to allow
time for NAC to enter the cells before treating with various concentrations of 8 nm ZnO
NP for 24 h. Viability was determined using the Alamar Blue cytotoxicity assay and a
fluorescent microplate reader.

Confocal Microscopy
Apoptosis Versus Necrosis
Mechanisms of ZnO NP-induced cytotoxicity were evaluated by confocal
microscopy using two different fluorescent staining techniques; acridine orange and
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Vybrant® Apoptosis Assay Kit #2- AlexaFluor® annexinV/propidium iodide by
Invitrogen (Eugene, OR). Acridine orange stains double stranded DNA and allows for
visualization of nuclear morphology. Invitrogen’s Vybrant annexin V assay makes use of
two different fluorescently labeled probes, annexin V and PI, to differentiate between
live, necrotic and apoptotic cells. Briefly, Jurkat T cells were suspended in complete
RPMI-1640 medium and plated at 5 × 105 on poly-D lysine coated glass bottom culture
dishes (P35GC-1.5 mm-14 mm-C) supplied by MatTek Corporation (Ashland, MA).
Samples were left untreated, treated with 0.3 mM ZnO NP, or with 100 nM okadaic acid
as a positive control for apoptosis. Following a 20 h incubation at 37 C (5% CO2), cells
were washed and stained with annexin V Ab/PI per manufacturer’s protocol or stained
with 5 μg/ mL acridine orange (AO) for 10 min at 37 C, followed by washing and
resuspension in PBS. Cells were visualized using a Zeiss LSM 510 META laser scanning
confocal microscope (Zeiss, Germany). Images were acquired using factory-set
dichronics (an argon laser set and two helium neon lasers) with either 63 × Plan
Apochromat 1.4 oil DIC or 100× Plan Fluar 14.5 oil objective. Image acquisition and
processing was performed using the LSM 510 META software.

NP Association with Immune Cells
NP-cell interactions were investigated using both flow cytometric analysis and
visualization using confocal microscopy. Bulk cultures of PBMC were left untreated or
treated with 5 mM FITC-doped ZnO NP for 16 h and cell types identified by staining
with fluorescently labeled Ab. Cell identification and FITC-NP/cell associations were
assessed using flow cytometry and both the percentage of fluorescent cells (FACS%) and
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mean fluorescence intensity (MFI) values for CD3+ T cells, CD4+ TH cells, CD19+ B cells
and CD14+ monocytes determined.
To examine NP intracellular localization versus extracellular plasma membrane
association, confocal microscopy was used to calculate the average number of FITCdoped NP/z-series slice in both Jurkat T and monocytic U937 cells. Cells were suspended
in RPMI-1640 medium and plated at 5 x 105 cells/mL on poly-L lysine coated glassbottom culture dishes (P35GC-1.5 mm-14 mM-C) supplied by MatTek Corporation
(Ashland, MA) for a 24 h to allow cellular adherence to plates. Jurkat T cell lymphoma
cells were left untreated and treated with 0.5 mM FITC-doped ZnO NP for 8 h at 37 C
(5% CO2). Cells from the monocytic cancer U937 cell line were left untreated and treated
with 0.3 mM FITC-doped ZnO for 20 h using identical parameters as above. Following
incubation, cells were washed with PBS and stained with fluorescent Ab for cell
identification; fluorescent anti-CD14 PE for U937 and fluorescent anti-CD3 for Jurkat.
After staining, cells were washed twice with PBS to remove excess Ab and reduce
fluorescent background signal before being visualized using a Zeiss LSM 510 META
laser scanning confocal microscope (Zeiss, Germany). Images were acquired using
factory-set dichronics (an argon laser set and two helium neon lasers) with either 63x
Plan Apochromat 1.4 oil DIC or 100x Plan Fluar 14.5 oil objective. Image acquisition
and processing was performed using LSM 51- META software. FITC-doped ZnO NP
were counted in multiple images for each cell type by examining individual slices from a
Z-series image. Orthogonal viewing was performed to verify intracellular localization of
NP compared to extracellular membrane association.
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Enzyme-Linked Immunosorbent Assay (ELISA)
To investigate the effect of ZnO NP treatment on cytokine production, a sandwich
enzyme linked immunosorbent assay (ELISA) was employed to allow for detection and
quantification of soluble cytokine released into culture medium. Human IFN-, TNF-α
and IL-12 were measured in primary peripheral blood mononuclear (PBMC) cells at a
concentration of 1 x 106 cells/mL. PBMC were left unactivated or activated with 1000
U/mL of IFN- (Peprotech, Rocky Hill, NJ) for 14 h and subsequently treated with
varying concentrations of 8 nm ZnO NP (0.05 mM, 0.1 mM and 0.2 mM) for 24 h.
Control (no activation and no NP treatment) samples were also included to allow for
background cytokine expression. Following incubation, cell-free supernatant was
harvested via successive 10 min centrifugations (2,000 rpm, 7,000 rpm and 13,000 rpm)
and cell supernatants stored at -80 C until analysis. ELISA was performed by the
UMAB Cytokine Core Laboratory (Baltimore, MD), with all samples analyzed in
triplicate and cytokine production expressed in pg/mL. IL-12 expression was measured in
PBMC left unactivated or activated with IFN- (1000 U/mL) both alone and in the
presence of ZnO NP. Expression of IFN- and TNF-α was assessed as described above
except that exogenous IFN- was not added to cell culture samples.

Data Analysis
All data was analyzed using SAS, Inc. software (Cary, NC). Data for Figures 2, 4,
5, 6, 7, 8, and 10 were analyzed using repeated measures analysis of variance (ANOVA)
with post hoc comparisons and significance levels defined as p < 0.05. Repeated
measures of variance analyses were used when two or more measurements of the same
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type were made on the same subject to determine statistical differences between the
means and to allow separation of within-subject variation from between subject variation.
Data for Figures 12, 13, and 18 were analyzed using a two-way analysis of variance
(ANOVA) to test for overall statistical significance of the model and post hoc
comparisons were used to test for statistically significant effects of treatment on cell
viability (p< 0.05).
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RESULTS

ZnO NP Display Cytotoxic Effects in T Cells Compared to Bulk ZnO
To determine if reduction of ZnO to the nano-scale alters the biological effects of
ZnO, we performed experiments comparing the effects of bulk micron-sized ZnO and
13 nm sized ZnO NP on isolated primary human CD4+ T cell viability. ZnO NP were
synthesized and characterized by our collaborators in the Punnoose lab by collection of
ZnO NP powder after separation from DEG medium via centrifugation. In agreement
with the XRD results (Reddy et al. 2007), transmission electron microscopy (TEM)
measurements were carried out to further investigate ZnO particle size and shape (Figure
1A) and average particle size of the NP estimated using the Scherrer relation was found
to be 13 nm, with a range of particle sizes (7-19 nm) observed (Figure 1B).
Experiments were performed testing identical concentrations of both ZnO NP and
bulk ZnO suspended in a phosphate buffered saline (PBS) solution on human CD4+ T
cells. Dual-color flow cytometry was used to simultaneously identify cells and assess cell
viability using propidium iodide (PI), a red fluorescent nuclear stain that enters only cells
with disrupted plasma membranes (Figure 2). No appreciable loss of viability was
observed in T cells treated with micron-sized bulk ZnO powder at any concentration
tested, conversely, ZnO NP treatment caused significant decreases in viabilities at
concentrations ≥ 5 mM (p=0.0001). This data indicates that T lymphocyte cytotoxicity
is limited to ZnO in the nanoscale size range, as no significant effect of bulk ZnO powder
was found at any of the concentrations tested (0.5 – 10 mM).
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Differential ZnO NP Toxicity to E. coli and S. aureus
For bacterial studies performed by our collaborator, Dr. Kevin Feris, ZnO NP and
bulk ZnO powders were suspended in diethylene glycol (DEG) to desired stock
concentrations and two different bacterial strains, E. coli and S. aureus, were treated with
varying concentrations of 13 nm sized ZnO NP. Results from these studies
demonstrated a differential inhibition of colony forming units (CFU) between the two
bacterial strains in response to ZnO NP treatment, with S. aureus exhibiting greater CFU
inhibition at lower concentrations compared to E. coli (Reddy et al. 2007).
To confirm ZnO NP definitively kill bacteria as opposed to merely inhibiting their
growth, we performed experiments in which bacteria were treated with 5 mM NP (E.
coli) or 2 mM NP (S. aureus) for 15 h and viability was determined using a 2-color
live/dead BacLight® bacterial viability kit (Invitrogen, Eugene, OR) in which populations
of live and dead bacteria were discriminated based fluorescence staining profiles. As seen
in Figure 3, substantial losses in viability were observed in both types of bacteria, with S.
aureus being the most susceptible (>59% loss of viability) followed by E. coli (>30%
loss in viability). This data combined with additional bacterial studies contributed by our
collaborator, Dr. Kevin Feris, and our own T cell viability demonstrate that T cells are
significantly less susceptible to ZnO NP-induced toxicity compared to both E. coli and S.
aureus at the same concentrations tested (p=0.000) (Reddy et al. 2007). Collectively,
these results indicate that ZnO NP toxicity occurs in a cell-dependent manner, with
significant differences in viability observed among different strains of prokaryotes (S.
aureus are killed at lower NP concentrations compared to E. coli) and between
prokaryotes and eukaryotes (T cells are more resistant to NP treatment compared to both
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strains of bacteria) (Reddy et al. 2007). To expand our understanding of factors affecting
ZnO NP toxicity, we conducted experiments to investigate the parameters affecting ZnO
NP toxicity in primary human immune cells.

Preferential Killing of Activated Versus Unactivated T Cells
To determine if differential toxicity to ZnO NP is dependent upon the
microenvironment or signaling status of eukaryotic cells, toxicity effects were determined
in resting primary human T cells and compared to cells activated through the T cell
receptor (TCR). Signal transduction through the TCR pathway is recognized as an
essential event required for resting T cells to enter the cell cycle and proliferate (Foell,
Hewes and Mittler 2007) and a second signal provided by ligation through the CD28
receptor protein augments TCR signaling and enables maximal T cell activation and
proliferation. For these studies, normal peripheral blood CD4+ T cells were isolated using
negative immunomagnetic selection and either activated with stimulatory TCR Ab (antiCD3), co-stimulated with both CD3 Ab (anti-CD3) and CD28 Ab (anti-CD28), or left
unactivated. The effects of ZnO NP on plasma membrane damage were assessed using PI
and flow cytometry. As shown in Figure 4A, the toxicity of ZnO NP to T cells is
dependent on the activation state of the cell, with resting T cells exhibiting the greatest
resistance to ZnO NP at all concentrations tested. The unactivated status of these cells
was verified by their lack of appreciable CD40L protein expression, a sensitive marker of
T cell activation Figure 4B. Conversely, T cells partially activated by stimulation through
the TCR pathway alone displayed significantly greater sensitivity to ZnO NP at all
concentrations (p=0.0007 for control versus CD3 at 1 mM, p=0.0009 at 5 mM and
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p=0.0052 at 10 mM NP). The partial activation status of these cells was verified by 38%
± 6.2% of the cells expressing membrane CD40L. Importantly, T cells activated through
both the TCR and CD28 co-stimulatory pathway showed an even greater sensitivity to
ZnO NP toxicity (e.g. 55% viability in CD3/CD28 activated versus 69% in CD3 activated
cells at 1 mM) which significantly differed from CD3 activated cultures at both 1 mM
(p=0.0044) and 5 mM NP (p=0.0246) concentrations. Staining for membrane CD40L
expression confirmed a greater extent of T cell activation in CD3/CD28 activated cultures
(67% ± 7.0% positive staining).
Control experiments using bulk micron sized ZnO powder or NP-free supernatant
showed no appreciable toxicity effect at any of the concentrations tested (e.g. viability
with bulk ZnO: 95 ± 0.5% at 0 mM, 96 ± 3% at 1 mM, 91 ± 3% at 5 mM, 91 ± 1% at 10
mM; 98% viability with NP-free supernatant equivalent to 1–10 mM). In addition to PI
uptake associated with disruption of plasma membrane integrity, NP-induced cell death
following ZnO NP treatment was supported by an increase (17%; MFI change of 48–
56) in light side scatter characteristics indicative of increased cell granularity and a
concurrent decrease (8%; MFI change of 156–144) in forward scatter reflects a decrease
in cell size at 10 mM NP concentrations. These results demonstrate significantly greater
cell death in activated T cells compared to resting cells over a relatively large range of
NP concentrations tested (1–10 mM), and toxicity varies with the extent of T cell
activation.
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Cancerous Cells Are Preferentially Killed by ZnO NP Compared to Normal Cells
Given that differential ZnO NP toxicity exists between quiescent T cells and those
activated with specific signals to trigger proliferation, experiments were performed to
determine whether continuously dividing cancer cells display an even greater sensitivity
to ZnO NP toxicity. Jurkat leukemic and Hut-78 lymphoma T cell lines were treated with
ZnO NP for 24 h and viability was determined by PI uptake (viability of cancer cell lines
was performed by lab member Janet Layne). Results from these experiments demonstrate
both T cell cancer lines display strikingly greater (28–35 fold) sensitivity to NP toxicity
compared to resting normal T cells (Figure 5A). Significant differences were observed
between Hut-78 and normal T cells (p=0.0101 and 0.0434 at 1 mM and 5 mM NP,
respectively) and Jurkat and normal T cells (<0.0001 at both 1 and 5 mM NP). No
appreciable loss of primary T cell viability was observed at NP concentrations (e.g. 0.5
mM) that effectively killed cancer T cells.
To validate experimental results, similar experiments were performed using the
LIVE/DEAD® viability assay (Invitrogen, Eugene, OR). This assay allows for the
simultaneous determination of live and dead cells in a sample by labeling live cells with
the Calcein AM dye that fluoresces only when cleaved by intracellular esterase enzymes
and the vital dye, EthD-1, which only enters dead/dying cells with disrupted cell
membranes. As shown in Figure 5B, nearly identical results were obtained using this
independent assay for viability, with ZnO NP displaying preferential toxicity against
cancerous cells compared to normal cells of identical lineage. It should be noted that no
statistically significant change in primary T cell viability occurs between untreated
primary control cells and these cells treated with low NP concentrations (0.2 and 0.5
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mM), while a significant decrease (p<0.0001) in Jurkat leukemia cell viability can readily
be seen at the lowest concentration tested (52% viable/48% dead at 0.2 mM), with no
live cancer cells detectable at 5 mM NP.

Memory T Cells Display Greater Sensitivity to ZnO NP-Induced Cytotoxicity
The activation of T cells in response to specific Ag results in a cascade of
intracellular signaling events and differentiation of ―naïve‖ T cells into ―memory‖ cells,
which can become activated much more readily upon subsequent exposure to the original
Ag (Surh and Sprent 2008). Given that activation thresholds and alterations in
intracellular calcium and signaling responses differ between naïve and memory T cells,
experiments were performed to determine whether memory T cells, display greater
sensitivity to ZnO NP toxicity compared to naïve T cells. Isolated PBMC were treated
with 8 nm ZnO NP for 22-24 h and viability assessed by PI uptake and flow cytometry.
Naïve CD3+ T cells were identified based on expression of the CD45RA (CD45RA+,
CD3+) surface marker, while memory T cells were defined as CD45RO+, CD3+. The
cytotoxic responses of naïve and memory CD3+ T cells to ZnO NP were compared to
bulk cultures of CD3+ T cells (containing a mixture of both naïve and memory cells)
from the same blood donor. As shown in Figure 6, memory T cells displayed
significantly greater sensitivity to NP toxicity compared to either naive T cells or bulk
cultures of CD3+ T cells (p=0.0044 and p=0.0244) at 10 mM ZnO NP. Naïve T cells
appeared more resistant to ZnO NP-induced cytotoxicity compared to total CD3+ T cell
samples, although statistically significant differences were not observed (p=0.08). These

55
results provide further evidence that susceptibility to ZnO NP-induced toxicity may be
related to the activation threshold and/or proliferation potential of the cell.

Kinetics of ZnO NP-Mediated Toxicity to Normal and Cancerous T Cells
To further elucidate differences in normal versus cancerous immune cells,
experiments were performed to determine and compare the kinetics of ZnO NP toxicity
in primary versus cancerous T cells. Cells were treated with ZnO NP and concentrations
chosen for each cell type (10 mM for primary T cells and 0.5 mM for Jurkat T cells) that
produce at least 75% cytotoxicity by 24 h exposure. Both primary T cells and Jurkat cells
display similar kinetics with appreciable losses in cell viability beginning as early as 8 h
post treatment, and full toxicity effects requiring a longer treatment period of 24 h
(Figure 7).

ZnO NP Cytotoxicity Is Dependent on Immune Cell Type
Our findings of differential ZnO NP toxicity based on cell type (e.g. eukaryotic
versus prokaryotic) and activation/proliferative potential were extended to determine
whether NP toxicity might also vary between different primary human immune cell
types. Comparisons of cytotoxic responses were made between normal T cells, B cells,
natural killer (NK) cells, and monocytes (Figure 8A). For these studies, freshly isolated
PBMC cell cultures containing all of these cell types were used, allowing for wellcontrolled uniform NP exposure. Following NP treatment for 23-24 h, various cell types
present in PBMC cultures were identified using Ab specific for T, B, NK or monocyte
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surface markers and evaluated for toxicity by staining with PI and analyzed by flow
cytometry.
As shown in Figure 8A, differences in NP-induced cytotoxicity are apparent
between the immune cells present in PBMC samples. CD3+ T lymphocytes, CD4+ T
lymphocytes and B lymphocytes display the greatest resistance to NP-mediated
cytotoxicity and possess a very similar IC50 of ~ 5.0 mM, with no significant differences
observed at any NP concentration evaluated (0.5 mM, 1 mM, 5mM and 10 mM). In
addition, no significant differences were observed between CD4+ T cells and CD3+ T
cells (e.g., 97%  1.5% for untreated and 28%  1.7% for 10 mM NP treated vs. 98%
1.2% for untreated and 34%  3.2% for 10 mM NP, respectively). In contrast, NK cells
were substantially more sensitive to NP-induced toxicity compared to T and B
lymphocytes, with an IC50 of 1.0 mM. Statistically significant differences were observed
between T and B lymphocytes compared to NK cells at NP concentrations of 1 – 5 mM
(p=0.0028 (T cells) and p=0.0003 (B cells) at 1 mM, p=0.0002 (T cells) and p= 0.0001
(B cells) at 2.5 mM, p=0.0019 (T cells) and p=0.0031 (B cells) at 5 mM and p=0.05 at 10
mM NP). Most striking is the increased NP-induced cytotoxicity observed in monocytes,
with >50% of monocytes killed at the lowest NP concentration tested (0.5 mM).
Statistically significant differences were observed between monocytes and NK cells (0.5
mM and 1 mM; p=0.0002 and p=0.0008, respectively), and monocytes compared to T
and B lymphocytes (p<0.0001 for both cell types at both concentrations tested).
Because adherent monocytes appear considerably more susceptible to NP-induced
cytotoxicity compared to the other immune cell subsets tested, additional experiments
were performed testing lower concentrations of ZnO NP on purified monocytes in order
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to determine the IC50 value. In these experiments, purified monocytes were treated with
varying concentrations of ZnO NP (0.0625 mM, 0.25 mM, 0.5 mM and 1 mM) and
viability evaluated using the fluorogenic redox Alamar Blue cytotoxicity assay. In
agreement with the monocyte data obtained from PBMC cultures, these results also
indicate a greater susceptibility to ZnO NP-induced toxicity in monocytes (compared to T
cells, B cells and NK cells) and reveal an IC50 for monocytes of 0.3 mM (Figure 8B). In
addition, the Alamar Blue cytotoxicity assay was performed on purified CD4 + T cells (110 mM) to confirm results obtained based on PI staining, and a similar IC 50 value of 5.4
was observed (data not shown).
Although these results indicate that monocytes are considerably more susceptible
to NP-induced cytotoxicity than other immune cell types tested, it is important to note
that these apparent differences may be related to significantly different cell culture
conditions. While T cells, B cells and NK cells grow as suspension cultures, monocytes
are adherent cells and grow as a monolayer. This difference in growth characteristic may
be a factor affecting ZnO NP toxicity and thus NP treatments between adherent cells
versus suspension cells may not be equivalent. Future experiments involving the growth
of these cell types in 3-dimensional cultures are needed to fully investigate this issue.
Nevertheless, these results indicate a significant difference in NP toxicity between
different primary immune cell types, with monocytes showing the greatest susceptibility,
followed by NK cells which are 3-fold less sensitive than monocytes, and T and B cells
which are ~ 17-fold and 5-fold less sensitive than monocytes and NK cells, respectively.
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Size Control of ZnO NP on Immune Cell Viability
To evaluate the relationship between ZnO NP size and its toxic potential, three
different sizes of ZnO NP (4 nm, 13 nm and 20 nm) were concurrently evaluated using
primary human CD4+ T cells as a model system. The three sizes of NP were made by our
collaborators by modification of the molar ratio of water to zinc acetate and the shape and
size confirmed by TEM (Figure 9) (Reddy et al. 2007). A ZnO NP concentration of 5
mM was chosen for these experiments given the observed IC50 value for T cells. After 24
h of NP exposure, viability was determined by PI uptake and flow cytometry. As shown
in Figure 10A, significantly greater cytotoxicity was observed with 4 nm NP (80.0% 
2.0%) compared to either 13 nm and 20 nm sized NP (p=0.0027 and p=0.0004,
respectively). Similarly, significantly less cytotoxicity was observed for 13 nm NP
(70.1%  8.0%) compared to 20 nm particles (44.0%  6.8%, p=0.05). To verify dosedependent ZnO NP toxicity based on NP size, we performed experiments testing 4 nm
versus 20 nm sized NP at varying concentrations (1 mM, 5 mM and 10 mM). As seen in
Figure 10B, significantly greater toxicity was observed using 4 nm NP compared to 20
nm NP at all concentrations tested (p=0.015 at 1 mM, p=0.004 at 5 mM and p=0.003 at
10 mM NP). These results demonstrate that ZnO NP-induced T cell toxicity increases
with decreasing NP size.
Towards understanding the mechanism of this response, it is important to note
that the band gap energy of NP is shown to increase with decreasing size (Yang, Liu,
Yang, Zhang and Xi 2009). As a greater band gap energy associated with smaller NP
could be expected to increase intracellular ROS production, studies were performed to
address this possibility. However, initial experiments were first performed to establish
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whether ZnO NP induce ROS production in immune cells and to determine the impact of
ROS production on cell viability.

ZnO NP Induce ROS Production
Several types of nanomaterials, including quantum dots and metal oxide NP, have
been shown to induce the generation of excess ROS, although only limited studies have
evaluated the ability of ZnO NP to induce ROS in normal/non-transformed mammalian
cells (Bergamini et al. 2004; Gojova, Guo, Kota, Rutledge, Kennedy and Barakat 2007).
To investigate oxidative stress as a mechanism of ZnO NP-induced cellular toxicity,
studies evaluated ROS production in primary CD3+ lymphocytes and CD14+ monocytes
in mixed cell PBMC cultures and in Hut-78 T cancer cells using the cell permeable dye,
DCFH-DA (Figure 11). In the presence of ROS, including hydrogen peroxide (H2O2) and
superoxide anion (O2-), DCFH-DA is oxidatively modified into a highly fluorescent
derivative that is readily detectable using flow cytometry. Following ZnO NP treatment
for 18-24 h, a modest increase in DCFH-DA fluorescence (~7.0 fold increase—
12.5/1.78) was observed in primary lymphocytes treated with 5 mM NP for 18 h (Figure
11A), and an even stronger induction was observed in Hut-78 T leukemic cells (14-fold
increase) (Figure 11B). Additionally, peripheral blood monocytes produced robust levels
(~25.1 fold increase) of ROS in response to ZnO NP, consistent with the greater capacity
of these cells for ROS generation (Figure 11C). Although increased ROS production was
detectable as early as 8 h of NP exposure, greater levels were apparent at 18–24 h.
To investigate the kinetics of ROS production, PBMC cultures were treated with
ZnO NP (1 mM and 5 mM) and ROS production measured in T cells and monocytes after
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6 h and 20 h of NP exposure, using flow cytometry to distinguish between cell types. As
shown in Table 1, modest amounts of ROS were detectable in monocytes (19% ROS
producing cells) as early as 6 h post ZnO NP exposure, yet no detectable ROS observed
in T cells at the corresponding concentration and time point. At 20 h of NP treatment,
appreciable ROS production was observed in T cells treated with 5 mM ZnO NP (~38%
ROS producing cells). Due to nearly complete cell death in monocyte cultures at 20 h
time points, no residual cell-associated ROS signal was observable.
These findings indicate ZnO NP are capable of inducing intracellular ROS in both
normal healthy immune cells (e.g. T cells and monocytes) and cancerous cells (e.g. Hut78), and demonstrate ROS production in monocytes occurs considerably earlier
compared to T cells. It is important to note that due to differing size and granularity
properties of the cell types examined, different instrument voltage parameters were
required which prevents direct comparisons of intrinsic levels of ROS between cell types.

ROS Production Is Dependent on ZnO NP Size
As earlier experiments demonstrated a dependence of cell viability on NP size
(smaller NP display greater toxicity compared to larger NP), we speculated that smaller
ZnO NP may induce greater amounts of ROS compared to larger NP. The relationship
between NP size and ROS production was investigated for three different sized ZnO NP
(4 nm, 13 nm and 20 nm) at two different NP concentrations (5 mM and 10 mM) in
mixed PBMC cell cultures (Figure 12). Following 3 h of treatment, ROS production was
evaluated using the ROS detection probe, DCFH-DA and fluorescence measured using a
microplate reader. A size dependent induction of ROS was observed at both NP
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concentrations, with 4 nm sized NP consistently inducing higher levels of ROS compared
to 13 nm or 20 nm sized NP. At equivalent 5 mM NP concentrations, significantly higher
levels of ROS were observed for 4 nm and 13 nm NP compared to 20 nm NP (4 -fold
relative increase (p=0.0165) and 3-fold increase (p=0.05), respectively). Similarly, 10
mM NP treatment resulted in significant differences in ROS production between all sizes
of NP with a 3.2-fold greater induction of ROS observed between 4 nm and 20 nm NP
(p<0.0001), a 1.9-fold increase observed between 13 nm and 20 nm NP (p=0.0297) and a
1.6-fold increase observed between 4 nm and 13 nm NP (p=0.005).

ROS Quenchers Mitigate ZnO NP-Induced Cytotoxicity
Due to the demonstrated ability of ZnO NP to induce ROS production in immune
cells, experiments were conducted to determine the causal role of NP-induced ROS as a
major mechanism of toxicity. Purified human CD14+ monocytes and CD4+ T cells were
pre-treated with N-acetyl cysteine (NAC), a tri-peptide that is readily oxidized in the
presence of ROS, prior to ZnO NP exposure. NAC acts to reduce ROS-induced cell
damage by augmenting cellular glutathione stores and is a well known ROS quenching
agent (Valko et al. 2005). Following 24 h of ZnO NP exposure, cell viability was
assessed using the Alamar Blue cytotoxicity assay and measured using a microplate
reader. Results reveal that 5 mM NAC significantly protects both monocytes and T cells
against NP-induced toxicity (p = 0.0001 and p = 0.0481, respectively) and implicates
ROS formation as a major mechanism of ZnO NP-induced toxicity in primary immune
cells.
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NP Association and Uptake
To evaluate NP-cell interactions, experiments were performed using FITC-doped
ZnO NP to monitor, quantify and compare NP internalization and extracellular membrane
association in immune cells.

NP Preferentially Associate with Monocytes Compared to Lymphocytes
Based on results indicating monocytes are killed at lower NP concentrations
compared to the other types of immune cells examined (e.g. T cells, B cells and NK
cells), we performed experiments to determine if NP cytotoxicity is correlated with the
degree of NP-cell association and/or NP uptake. Fluorescent FITC encapsulated ZnO NP
(FITC-ZnO NP) prepared by our collaborators (Wang et al. 2009) were used to quantify
the extent to which NP physically and stably associate with cells using both flow
cytometric analysis and confocal microscopy. In one set of experiments, freshly isolated
PBMCs were treated with 5 mM FITC-ZnO NP, or left untreated, and multi-color flow
cytometry used to simultaneous identify monocytes and lymphocyte populations present
in the PBMC culture, as well as evaluate relative increases in FITC-NP signal in these
two cell types. As shown in Table 2, all immune cell types evaluated (T, B, and
monocytes) show strong NP association, with 78-98% of cells displaying at least some
level of positive FITC fluorescence compared to control cells cultured in the absence of
NP. However, a 9.3-13.7 -fold increase in the number of NP associating with any given
monocyte compared to individual T and B lymphocytes was observed as indicated by
changes in the mean fluorescence intensity (MFI) (T and B lymphocytes displayed
similar MFI values). These results demonstrate that ZnO NP preferentially associate with
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monocytes (MFI: 131.2) compared to lymphocyte subpopulations (MFI: 9.84 for CD3+,
MFI: 14.1 for CD4+ TH and MFI: 9.61 for B cells), although whether this simply reflects
initial extracellular membrane-NP interactions or intracellular NP localization is not
discernable using this experimental approach.

NP Preferentially Associate with Activated T Cells
Based on differences in activated versus unactivated T cells to ZnO NP-induced
toxicity and to gain further insights into mechanisms of differential cell toxicity,
experiments were performed to determine whether NP preferentially associate with
activated T cells compared to resting T cells. FITC encapsulated ZnO NP (FITC-ZnO
NP) were prepared as described (Wang et al. 2009) and their fluorescence properties used
to monitor cell uptake/association. Primary CD4+ T cells were both left unactivated or
activated with CD3/CD28 Ab and treated with 5 mM FITC-ZnO-NP for 4 h. Dual color
flow cytometry was used to analyze changes in the FITC-NP signal on gated CD4+ T
cells. Results demonstrate a low NP associated fluorescence signal (12.5% FITC
positive) in resting T cells, while a substantially greater FITC signal (48.4% positive) was
observed for activated T cells (Figure 14). A dose-dependent uptake/association of FITCZnO-NP was noted with greater NP association at 5 mM compared to 1 mM
concentrations (3.3 greater attachments at 5 mM).
At the early time points evaluated in these studies, NP labeling did not appear to
reflect a generalized increase in membrane permeability as no PI uptake indicative of
cytotoxicity was observed following 4 h of exposure with 5 mM FITC-ZnO-NP (data not
shown). However, the expected loss of cell viability (73% ±7.3% s.e., n = 3 with 1.25
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mM) was detected upon extended 24 h exposure, indicating that FITC ZnO-NP behave
similarly to unlabeled ZnO NP. Collectively, these results indicate that the cellular
processes accompanying T cell activation (e.g. increased membrane protein expression,
cell cycle progression) result in changes that promote strong physical interactions and
consequent intracellular uptake of NP.

NP Uptake by Jurkat T Cells
NP uptake and internalization studies were performed using Jurkat T cells to
explore NP-immune cell interactions. Jurkat T cells were treated with FITC-ZnO
particles (green fluorescence) for 8 h, and washed extensively to remove unattached
extracellular particles and reduce background staining. Cells were stained with an antiCD3 PE-conjugated Ab (red fluorescence) and confocal images taken using live cells to
avoid internalization artifacts resulting from cell fixation. Figure 15 (panels B-D) shows
consecutive three-dimensional slices through a single Jurkat T cell and images
demonstrate internalization of a green fluorescent FITC-ZnO particle with intracellular
localization being confirmed by viewing along orthogonal directions. Individual confocal
image slices were taken at intervals of 200 nm thickness (comparable in size to the NP),
thus only one internalized particle is shown in the presented focal plane. However, at
least six internalized NP were observed in this particular cell with additional
internalizations likely but too proximate to the plasma membrane to accurately resolve.
The presence of such internalized FITC-ZnO particles was confirmed in multiple
cells present on the culture slide. Figure 15A reflects NP background staining and was
obtained by treating with an identical concentration of NP and sample washing regime as
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for cell cultures (Wang et al. 2009). Although these findings do not determine specific
intracellular locations of the internalized particles, they do demonstrate the ability of
immune cells to endocytose/phagocytose NP and show a correlation between NP
internalization/membrane association and susceptibility to ZnO NP-induce cytotoxicity.

ZnO NP Induce Apoptosis
Published research has demonstrated ZnO NP induce dose-dependent apoptotic
and necrotic forms of cell death in non-human mammalian cells, with lower
concentrations of ZnO NP inducing apoptosis and higher concentrations resulting in
necrosis (Jeng and Swanson 2006). However, very little is known about ZnO NP-induced
cell death in human cells, specifically human immune cells. To this end, experiments
were performed to evaluate mechanisms of ZnO NP-induced cell death (e.g. apoptosis
and necrosis) in T cells at concentrations previously determined to cause significant cell
death. Jurkat cells were treated with 0.3 mM NP for 20 h and apoptosis evaluated using
two different experimental approaches. In the first, cells were stained with a green
fluorescent annexin V Ab which reacts against externalized phosphatidylserine, a
characteristic of apoptotic cells, and the red fluorescent propidium iodide dye which
stains both late-stage apoptotic and necrotic cells displaying permeable membranes
(Figure 16). As expected, viable control cells show only very weak staining with annexin
V Ab and no detectable staining with PI (Figure 16 panels A-C). Conversely, cells treated
with ZnO NP stain positive with the apoptotic marker (e.g. two out of the four cells in
panel F and four out of five cells in panel G show green fluorescence only). Some dually
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stained cells were also observed as expected for late-stage apoptotic cells with permeable
membranes.
To further verify NP-induced apoptosis, similar cell cultures were stained with the
DNA dye, acridine orange (Figure 17), which is used to detect apoptotic morphology
characterized by nuclear fragmentation, cellular shrinkage, and chromatin condensation.
These morphological changes were observed in NP treated cultures (Figure 17C) and
cells treated with the apoptosis inducer okadaic acid (Figure 17B), but not in control
samples (Figure 17A). Collectively, results from these studies indicate ZnO NP toxicity
to immune cells can occur by an apoptotic process.

ZnO NP Induce Pro-Inflammatory Cytokine Expression
The pro-inflammatory potential of NP has been shown to be dependent on a
variety of factors such as nanomaterial, size, method of delivery, etc. (Duffin, Tran,
Brown, Stone and Donaldson 2007). To elucidate the pro-inflammatory potential of ZnO
NP on primary human immune cells, various cytokines (IFN-, TNF-α and IL-12) were
measured in resting (unactivated) and IFN--primed primary human immune cells. These
cytokines were chosen because they represent critical pathways involved in both the
inflammatory response and immune cell activation and differentiation. Freshly isolated
PBMC were left untreated or treated with varying concentrations of 8 nm ZnO NP for 38
h. After incubation, cell-free media was harvested and cytokine levels measured using an
ELISA assay (performed by Cytokine Core Laboratory, Baltimore, MD). Additionally,
some cell samples were primed with IFN- (1000 U/mL) before addition of NP to assess

67
the effect of activation status on cytokine production (specifically, IL-12) in response to
NP treatment.
Results from these studies demonstrate significant dose-dependent increases in
IFN- and TNF-α in response to ZnO NP treatment at all concentrations tested (0.05 mM,
0.1 mM and 0.2 mM) (Figure 18A and B). Interestingly, while ZnO NP treatment did not
induce appreciable amounts of IL-12 production in resting cells, significant dosedependent increases were observed in IFN--primed cells (Figure 18C). The inability of
ZnO NP to induce IL-12 in resting cells is not altogether surprising as naturally occurring
IL-12 production is typically only seen in antigenically activated immune cells (e.g. DC,
monocytes, T cells) (Maranda and Robak 1998). These findings indicate ZnO NP are
capable of inducing at least some key components of inflammation, and further suggests
that a Th1-mediated immune response may be elicited, which is the type of immunity
desirable for eradicating cancer and virally infected cells (Tau et al. 2000).

SnO2 NP and CeO2 NP Appear Less Toxic to T Cells Compared to ZnO NP
Initial experiments were performed to compare ZnO NP toxicity in T cells to two
other common types of metal oxide NP, namely SnO2 NP and CeO2 NP (Figure 19).
CD4+ T cells were left untreated or treated with 10 mM NP of either SnO2 NP or CeO2
NP for 22-24 h and dual color flow cytometry was used to simultaneously identify cells
and test cell viability using PI. Preliminary findings indicate both SnO2 NP and CeO2 NP
fail to kill T cells at 10 mM of NP treatment (90% viability), a concentration shown to
cause significant ZnO NP-induced T cell death (<30% viability, Figure 8A).
Interestingly, treatment with SnO2 NP and CeO2 NP caused a dramatic increase in cell
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granularity (SSC) with no concurrent change in size (FS), and gating on these highly
granular cells revealed an absence of PI signal, indicating normal cell viability. As
increases in granularity (SSC) properties with no concurrent change in size (FS) may be
indicative of phagocytosis/endocytosis (Coester, Nayyar and Samuel 2006; Elamanchili,
Diwan, Cao and Samuel 2003), these preliminary results suggest SnO2 NP and CeO2 NP
are taken up by T cells, but unlike ZnO NP, may not cause appreciable cell death.

69

DISCUSSION

Nanomaterials are of particular interest due to the unique physical, chemical and
biological properties that can accompany reduction to the nanoscale (Medina, SantosMartinez, Radomski, Corrigan and Radomski 2007). Unlike micron-sized bulk materials,
the properties of nanomaterials are governed by principles of both classical and quantum
physics and are attributed, at least in part by an increased surface area to volume ratio
with decreasing size. This translates into distinctive size-dependent characteristics, and
much research is devoted to gaining an understanding of how these characteristics impact
biological and cellular systems (Fortina, Kricka, Surrey and Grodzinski 2005).
NP are being explored for a variety of different biomedical applications and are
already found in many commercial products. Metal oxide NP, specifically ZnO NP, are
one such type of NP frequently used in sunscreens and cosmetics due to its increased
transparency and enhanced UV protection (Fan and Lu 2005). ZnO NP are also
recognized as semi-conductor quantum dots, which are a class of NP which exhibits sizedependent fluorescent properties that render them useful in biosensing (e.g. tumor
detection) and enhanced tissue imaging (Bawarski, Chidlowsky, Bharali and Mousa
2008). Understanding how NP interact and impact cells is of critical importance from an
environmental health and safety standpoint, and also may provide for novel NP
applications.
Research has provided evidence that specific properties such as size, shape and
surface reactivity all contribute the cytotoxic potential of NP (Igarashi 2008). Our results
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demonstrate differences in ZnO NP-induced toxicity to immune cells based on several
parameters such as cell type, cell activation status, proliferative potential, NP size, the
extent of NP-cell physiological interactions, and implicate ROS production as a major
mechanism of cytotoxicity. Additionally, results indicate ZnO NP elicit pro-inflammatory
cytokine production from immune cells. Collectively, these findings illustrate differential
ZnO NP effects and suggest a potential clinical relevance for ZnO NP in the treatment of
diseases such as cancer and autoimmunity based on the cell-selective cytotoxic properties
of these NP.

We first evaluated the effect of ZnO NP compared to larger micron-sized ZnO on
purified human CD4+ T cell viability as a representative immune cell type due to the
important role of T cells in regulating the immune response. Our findings demonstrate
dose-dependent decreases in cell viability in response to ZnO NP treatment at
concentrations of bulk ZnO where no appreciable loss in viability is observed (Figure 2).
These results indicate that when reduced to the nano-scale, ZnO acquires unique size
dependent properties resulting in altered toxicity thresholds compared to what is typically
observed for this bulk material. To further explore this issue, T cell results were
compared to ZnO NP studies performed by our collaborators, Drs. Kevin Feris and Alex
Punnoose, showing bacteria (E. coli and S. aureus) inhibition in response to ZnO NP
treatment, and reveal both types of bacteria are killed at lower concentrations compared
to T cells (data not shown, p<0.0001) (Reddy et al. 2007). Although there were
differences in certain experimental conditions between the bacteria and T cell studies,
including media type (i.e. LB for bacteria and RPMI for T cells) and vehicle type for NP
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delivery (i.e. DEG for bacteria and PBS for T cells), results are still of interest as both
types of culture media contain large proteins, carbohydrates and other factors which
might influence NP toxicity and no appreciable vehicle effect was observed for either cell
type in control cells. Our studies further demonstrate that differences in NP-induced
cytotoxicity exist between types of common bacteria, with S. aureus being more
susceptible than E. coli (Figure 3) (Reddy et al. 2007). These differences in NP
susceptibility observed among bacteria strains and between bacteria and human cells
suggest the possibility of exploiting ZnO NP for use as novel anti-microbial agents in
which potentially harmful bacteria are selectively eliminated and normal human cells are
spared. As such, future research is necessary to build on these findings for further
elucidation of factors underlying ZnO NP cytotoxicity and investigating ZnO NP effects
on other types of bacteria.

To further explore mechanisms underlying differential ZnO NP cytotoxicity, we
extended our studies to investigate whether the activation status of immune cell
influences toxicity. CD4+ T lymphocytes were utilized as a representative cell type given
their critical role in protective immunity, the frequent negative effects of commonly used
chemotherapeutic agents on cells of hematopoietic lineage, and the ability of self-reactive
T cells to contribute to the development of autoimmune diseases. ZnO NP- cell responses
were evaluated in normal primary resting T cells and compared to identical cultures in
which cells were either activated through the T cell receptor (TCR) signaling pathway or
via both TCR and CD28 co-stimulation pathways. Results demonstrate significantly
greater resistance to ZnO NP-induced toxicity in quiescent T cells compared to TCR
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stimulated cells, and even greater sensitivity in TCR/CD28 co-stimulated T cells (Figure
4). Additionally, we found activated T cells associate with ZnO NP to a greater extent
compared to resting T cells (Figure 14), consistent with the greater susceptibility to ZnO
NP-induced toxicity in activated cells compared to resting cells. The preferential killing
and greater NP association observed in activated cells relative to quiescent cells of the
same lineage suggests that mechanisms of ZnO NP toxicity may be related to the
proliferative potential of the cell and subsequent NP-cell interactions. In a number of
autoimmune diseases, including multiple sclerosis and psoriasis, self-reactive T cells are
a pathogenic subset underlying disease processes and exist in a predominately activated
state as they are continually exposed to specific Ag present in normal body tissue
(Wagner 2007). Because only a very small percentage of the total T cell repertoire are
self-reactive and pathogenic in autoimmunity, the ability of identical concentrations of
ZnO NP to preferentially induce cytotoxicity in self-reactive activated T cells while
leaving the unactivated T cell repertoire largely intact and immunity uncompromised
represents an incredibly attractive approach for treatment. Thus, these findings may
provide a foundation for the development of ZnO NP-based therapeutics, where diseasecausing cells are targeted by attachment of Ab to ZnO NP directed against proteins
expressed predominantly on activated T cells, such as CD40L and OX40 (Taraban et al.
2002). However, additional research is required to further elucidate factors influencing
NP toxicity and in vivo studies are necessary to gain a more thorough understanding of
how ZnO NP impact the immune system as functioning unit.
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The greater toxicity of ZnO NP against activated T cells led to experiments
testing the effects of ZnO NP toxicity in memory versus naïve T cells (Figure 6), since
memory T cells are recognized to respond and proliferate much faster to a previously
encountered Ag compared to naïve (Surh and Sprent 2008). For these experiments, bulk
cultures of PBMCs were treated with ZnO NP and T cell types present in PBMC cultures
(naïve, memory and a mixture of both) identified by cell-surface markers. Our results
demonstrate that memory T cells are more susceptible to ZnO NP-induced cytotoxicity
compared to antigenically inexperienced naïve T cells, and support the hypothesis that
ZnO NP toxicity is dependent on the metabolic status and proliferative capacity of the
cell.

Differences in ZnO NP cytotoxicity based on cell type (e.g. prokaryotes versus
eukaryotes) and cell activation status lead to experiments in which normal cells were
compared to cancerous cells of the same lineage, as cancer cells exhibit uncontrolled
proliferation and robust metabolic activity (Hanley et al. 2008). Results reveal that
cancerous T cells are markedly more susceptible (~28-35 times) to ZnO NP mediated
toxicity compared to their normal counterparts (Figure 5), and similar kinetics were
observed for NP-induced toxicity to both cancer and normal T cells (Figure 7). These
findings may be of clinical importance as one of the greatest challenges facing
chemotherapy is the inability of anticancer drugs to effectively distinguish between
normal and transformed tissue (Nie, Xing, Kim and Simons 2007; Hellman 1980).
Although many commonly used chemotherapeutic drugs target rapidly dividing cells,
many suffer from a relatively low therapeutic index, that is, the ratio of toxic dose to
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effective dose (Huang and Oliff 2001). This limitation frequently causes a broad range of
toxicities leading to dose limiting toxicity and a concomitant reduction in antitumor
efficacy. The preferential toxicity of ZnO NP towards cancerous T cells is of substantial
magnitude, especially in comparison to ex vivo indices reported for other commonly used
chemotherapeutic agents using similar cell viability assays. For example, therapeutic
indices of ≤ 10 have been reported for two commonly used chemotherapeutic agents,
doxorubicin and carboplatin, against a variety of tumors including acute myelogenous
leukemia, non-Hodgkin’s lymphoma, ovarian, and other solid tumors (Bosanquet and
Bell 2004). Additionally, the similar kinetics observed in cancer and normal T cells
suggests ZnO NP-induced cytotoxicity occurs in a predictable time-dependent fashion,
regardless of cell type and susceptibility (Figure 7), and is a critical piece of information
when considering materials for drug development.
The inherent differential toxicity of ZnO NP against activated and rapidly
dividing cancer cells raises exciting opportunities for their potential use as anticancer
agents, and the selectivity of these nanomaterials may be further enhanced by the
covalent attachment of monoclonal Ab, peptides, and small molecules to tumorassociated proteins which would allow for selective targeting of the disease-causing
cancer cells for in vivo studies using animal models. However, care must be taken when
extrapolating these observed differential cell responses to all cell types until further
studies have been conducted evaluating the effects of ZnO NP across many cell lineages.

The preferential ZnO NP-induced killing of highly proliferative cancer cells and
activated T cells indicates a need to examine the effects of ZnO NP toxicity on various
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types of resting primary immune cells. To assess this, the effect of ZnO NP on cell
viability was measured in primary human T cells, B cells, NK cells and monocytes in
mixed PBMC cell cultures and cell identification achieved by labeling cell-specific
surface markers. Testing the effects of ZnO NP in bulk immune cell cultures is
advantageous, as it takes intercellular interactions and cell-signaling effects into account,
and is a better estimation of in vivo effects and physiological relevancy. Of the four cell
types tested, monocytes were shown to be the most susceptible to ZnO NP-induced
toxicity, with 18-fold and 6-fold differences in viability observed compared to T and B
lymphocytes and NK cells, respectively (Figure 8). As immune cells are highly diverse
and possess unique phenotypes based on specific immune cell function, our findings
indicate ZnO NP toxicity may be dependent on differences in cell-specific properties
such as growth characteristics, size, cell-surface receptors, mechanisms of particle
uptake, capacity for ROS production, etc.
For example, unlike T, B, and NK cells which grow in vitro as free floating cell
suspensions, monocytes are an adherent cell type and grow in culture as a surface
monolayer. This property may influence the effective concentration of ZnO NP treatment
for adherent monocytes as NP aggregates form and settle on top of the monocyte layer.
Future studies are needed to determine the extent to which these differing attributes (e.g.
adherence versus suspension) contribute to ZnO NP toxicity, and one potential approach
would be altering adherent cell methodology by growing adherent cells on a 3dimensional structure within culture media before ZnO NP addition.
Additionally, physiological differences between phagocytes and non-phagocytic
cells, such as increased particle uptake by phagocytes, larger phagocyte size, and greater
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capacity for ROS formation (generated for intracellular destruction of bacteria in the
phagosomes) may help to explain increased ZnO NP susceptibility in monocytes
compared to lymphocytes. Phagocytes may be more likely to ingest NP aggregates, and
the larger cell size may allow more room for intracellular NP accumulation, and
consequently, increased intrinsic ROS production. As monocytes already produce greater
levels of ROS compared to lymphocytes, excess ROS generated in response to NP
exposure may result in overwhelming oxidative stress mechanisms leading to cell death.
The production of ROS may also factor into why NK are killed at lower concentrations of
ZnO NP compared to T and B lymphocytes as published research indicates that ROS is
used by cytotoxic NK cells for induction of caspase-independent induced target cell
killing (Martinvalet, Zhu and Lieberman 2005), although additional research is required
to substantiate this hypothesis.

Although phagocytosis is not a major defense mechanism used by T, B and NK
cells, these cells are capable of intracellular uptake of certain particulate matter by
endocytosis (e.g. pinocytosis and receptor-mediated endocytosis), which is used by all
cells for accessing macromolecules and other essential molecules, and trafficking of cell
surface receptors (Rogers and Basu 2005). To explore whether increased ZnO NP
sensitivity is correlated with NP uptake and association, fluorescent FITC-doped ZnO NP
were used to investigate NP-cell interactions. Consistent with our toxicity findings,
observations reveal both T cells (Figure 15) and monocytes capable of NP uptake, and
demonstrate greater NP association in monocytes compared to both T and B lymphocytes
(Table 2). Although exact mechanisms by which nonfunctionalized NP (NP without
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functionalized localization or target sequences), such as ZnO NP, interact with cells is not
yet fully understood, several studies have provided evidence that both negatively and
positively charged NP (specifically QD) can be endocytosed by human cells and are
capable of nuclear penetration (Ryman-Rasmussen, Riviere and Monteiro-Riviere 2007;
Jaiswal, Mattoussi, Mauro and Simon 2003). Based on these findings, future experiments
are warranted to investigate exact mechanisms of ZnO NP uptake and association
between different cell types.
Our results support other studies showing significantly greater NP QD (CdTe and
CdSe/ZnS) uptake in phagocytic cells compared to NP uptake by non-phagocytic cells,
and indicate that specific structural and physiological differences between different
immune cell types, such as adherence and phagocytic ability, significantly contribute to
ZnO NP-induced toxicity, allowing for predictions of increased NP susceptibility based
on these characteristics for other cell types. The extent to which cells internalize and
associate with ZnO NP may be an essential component of selective ZnO NP toxicity and
although specific mechanisms of ZnO NP cellular uptake cannot be determined from
these experiments, existing research indicates QD are capable of exploiting the cell’s
active transport machinery for NP delivery to discrete intracellular and intranuclear
destinations (Nabiev et al. 2007). Future research directed at exploring specific
mechanisms of ZnO NP uptake such as the contributions of receptor-mediated compared
to non-receptor mediated endocytosis and factors influencing NP uptake (e.g. NP charge,
dissolution, NP size, etc.) may shed further light on this issue.

78
Oxidative stress, as seen in excessive ROS production, is implicated in
degenerative and detrimental biological processes such as aging and disease development
(e.g. cancer, Alzheimer’s disease), and a number of studies indicate that certain
nanomaterials, including metal oxide NP, have the potential to exhibit spontaneous ROS
production based on material composition and surface characteristics, while other
nanomaterials trigger ROS production only in the presence of select cell systems (Xia et
al 2006; Lovric, Cho, Winnik and Maysinger 2005; Long, Saleh, Tilton, Lowry and
Veronesi 2006). Results from our flow cytometry experiments demonstrate ZnO NP
induce ROS production in both primary and cancer immune cells (specifically T cells and
monocytes) and are consistent with other reports demonstrating ROS production in biotic
environments following ZnO NP exposure (Xia et al. 2008b). Our findings show ZnO
NP-induced ROS formation occurs in a concentration, time, and cell-type dependent,
with higher levels observed in primary monocytes compared to primary T cells, which is
consistent with the ability of these cells to generate large amounts of ROS during an
immune response. Interestingly, immortalized T cells produced greater levels of ROS
than primary T cells which may mechanistically underlie the greater susceptibility of
cancerous T cells to NP-mediated toxicity (Figure 11).
These findings have important implications regarding mechanisms of cellular
toxicity, as elevated ROS production that exceeds the capacity of the cellular antioxidant
defense system causes cells to enter a state of oxidative stress which results in damage of
cellular components such as lipids, proteins, and DNA (Lovric et al. 2005; Xia et al.
2008b). NP-induced ROS production may activate transcription factors such as NK-kB
and AP-1 that control the transcription of pro-inflammatory genes (Monteiller et al.
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2007), however, it is still enigmatic under which conditions cellular demise induces an
immune response or remains immunologically silent, and under which circumstances
apoptotic or necrotic cells are immunostimulatory or tolerogenic (Kepp et al. 2009).

The causal role of ROS generation in NP-mediated cytotoxicity was validated by
experiments using the ROS quencher, NAC. Results from these experiments
demonstrated significantly greater viability in cells (e.g. primary monocytes and CD4 + T
cells) pre-treated with NAC before NP treatment compared to cells treated with NP alone
(Figure 13). These results provide important insights implicating ZnO NP-induced ROS
production as a primary mechanism of immune cell cytotoxicity and led to studies
investigating the effect of NP size on ROS production.

Nano-scaled particles exhibit discontinuous crystal planes, increases in structural
defects and changes in the electronic configuration, resulting in altered electronic
properties on the particle surface which are directly related to particle size (Oberdorster et
al. 2005). We evaluated the effect of ZnO NP size on immune cell toxicity and ROS
production using 3 different sizes of ZnO NP (4 nm, 13 nm and 20 nm) at multiple
concentrations. Findings from our studies demonstrate an inverse relationship between
ZnO NP size and immune cell viability (Figure 10) which is consistent with reports using
other NP systems and materials showing greater cytoxicity associated with smaller NP
size (Nair et al. 2008). In agreement with our toxicity results, we found smaller ZnO NP
(4 nm) induce greater amounts of ROS in immune cells compared to larger ZnO NP (e.g.
20 nm) (Figure 12) which may be due to smaller particles having larger reactive surface
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areas compared to larger particles (Nel, Xia, Madler and Li 2006). In general, biological
activity increases with decreasing particle size and the opposing trend of increased
toxicity and ROS production with decreasing NP size indicates that if ZnO NP were to be
employed for use in therapeutics, the smallest NP size available should be considered for
use.
Particle size, shape, and chemical composition have been shown as principal
factors controlling NP-cellular interactions and toxicity to mammalian cells (Yang et al.
2009). Another factor shown to contribute to the intracellular interactions with NP and
NP-induced cytotoxicity is the dissolution of ions from metal and metal oxide NP,
although the extent to which ion dissolution contributes to NP toxicity is unclear (Gojova
et al. 2007; Cheng 2004). The dissolution of copper, cadmium and zinc ions from NP
have been shown as major contributors in NP-induced toxicity to mammalian cells,
especially in low pH conditions, and increasing ion dissolution has been correlated with
decreasing particle size (Midander et al. 2009; Wang, Nagesha, Selvarasah, Dokmeci and
Carrier 2008; Aruoja, Dubourguier, Kasemets and Kahru 2009). In one study, researchers
found dissolution to play a significant role in ZnO NP-induced toxicity by disturbances in
cellular zinc homeostasis resulting in lysosomal and mitochondrial damage and
subsequent cell death (Xia et al. 2008a). However, conflicting research demonstrates
minimal effects of Zn2+ ion dissolution alone on cell viability, and indicates NP size and
surface chemistry as significant determinants of NP-induced toxicity (Yang et al. 2009)
by ascribing the toxicological effects of ZnO NP not to particle dissolution, but to
specific NP surface properties as determined by chemical composition (Yang et al. 2009).
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The effects of NP size on toxicity have also been shown to be related to NP
uptake (smaller NP are internalized to a greater extent compared to larger NP) and
mitochondrial membrane association (Yang et al. 2009; Tarantola et al. 2009). The
inconsistencies that currently exist in the scientific literature indicate that additional
studies are warranted in these areas. Nonetheless, our research supports other studies by
demonstrating a dependency of cytotoxicity on NP size and is novel in showing these
effects specifically using ZnO NP in primary human immune cells.
The reduction in size of many materials to the nano-scale increases toxicity in
many types of materials; however research suggests that other types of materials have
cytoprotective properties at the nano-scale. We performed initial experiments to test
differences in toxicity between CeO2 NP and SnO2 NP to primary T cells for comparison
to results obtained using ZnO NP (Figure 19). Results from these preliminary
experiments suggest that unlike ZnO NP, CeO2 and SnO2 are not toxic at 10 mM NP
treatment, however, the increased granularity observed in response to NP treatment
suggests NP uptake. These findings are in agreement with other published reports
evaluating the effects CeO2 NP on mammalian cells where it is hypothesized that the
antioxidant properties of CeO2 NP suppress ROS production and exert cellular resistance
to exogenous sources of oxidative stress, thus protecting cells from oxidative injury
(Chen, Patil, Seal and McGinnis 2006; Tarnuzzer, Colon, Patil and Seal 2005). Although
suggestive, more research is required to further explore this issue as well as testing the
effects of additional types of metal oxide NP on human immune cells.
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As there is increasing evidence that elevated ROS acts as a critical signaling
molecule in the induction of apoptosis by various stimuli (Jeng and Swanson 2006),
studies were performed to determine mechanisms of ZnO NP-induced cell death. Results
presented in Figures 16 and 17 provide strong evidence that ZnO NP cytotoxicity occurs
by apoptotic processes in cells of T lymphocyte lineage at the concentrations tested.
Research suggests the amount of ROS produced and intensity of oxidative stress may
determine mechanisms of cell death, specifically selection between apoptosis and
necrosis, with higher levels of ROS associated with the latter (Baigi et al. 2008). In
contrast to apoptotic processes, necrotic forms of cell death are generally considered
immunostimulatory (e.g. capable of eliciting a comprehensive immune response) and
pro-inflammatory. However, the conditions under which cellular demise is
immunostimulatory (e.g. elicits a comprehensive immune response) are not yet fully
understood and controversy exists over whether apoptotic or necrotic cells are
intrinsically immunogenic or tolerogenic (Kepp, Tesniere, Zitvogel and Kroemer 2008).
Recent evidence indicates that in contrast to scientific dogma concerning
apoptotic cellular mechanisms, apoptosis (especially late stage apoptosis) may not be
morphologically homogenous as evidenced by the surface expression of several proteins
shown to promote antigen presentation and subsequent immune cell activation (Kepp et
al. 2008). Distinguishing mechanisms of cell death (e.g. apoptosis versus necrosis) is a
critical component of drug development as moderate levels of immune cell activation are
beneficial for eliminating disease-causing cells, such as tumor cells, while overstimulation of the immune response has been shown to promote tumorgenesis.
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These studies indicate that a primary mechanism of ZnO NP cytotoxicity may
precede ROS generation which then underlies the induction of apoptosis, a process that
may be prevented by antioxidant and ROS quenchers. These observations may provide
the basis for the development of new rational strategies to protect against ZnO NP
toxicity or enhance the desired destruction of pathogenic cell types. Further research is
needed to establish if the mechanism of ZnO NP-induced cell death (e.g. apoptosis or
necrosis) occurs in a dose-dependent manner if this material is to be considered for
therapeutic purposes as manipulation of this property may allow for more effective
elimination of diseases-causing cells.

Certain metal oxide NP have been shown to induce pro-inflammatory responses,
and some cytokines have been reported as induced by various metal oxide NP (Park and
Park 2009). Additionally, the relationship between oxidative stress and inflammation is
well established and studies have provided evidence which suggests ROS-induced
inflammatory responses play a critical role in the cytotoxic effects (both apoptotic and
necrotic) of different types of NP both in vitro and in vivo (Johar et al. 2004). We
evaluated the effect of several different concentrations of ZnO NP on the expression of
three different pro-inflammatory cytokines, IFN-, TNF-α, and IL-12, using bulk cultures
of PBMCs. The role of TNF-α in inflammation is well characterized and has been shown
to be an important regulator of acute inflammation, capable of influencing many aspects
including infiltration of inflammatory cells into tissue, activating phagocytosis, inducing
apoptosis in virally infected and tumor cells, chemotaxis of monocytes, and promoting
Th1 differentiation. Notably, this cytokine received its name by the potent anti-tumor
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activity it possesses when used at appropriate concentrations. However, high levels and
chronic exposure to TNF-α have been shown to be detrimental and are associated with
many of the symptoms associated with autoimmune disease. Our results demonstrate
significant dose-dependent increases in TNF-α in response to ZnO NP compared to
control cultures (Figure 18B). This dose-dependent response is important when
considering ZnO NP for biomedical purposes as it allows for controlling the levels of
TNF-α needed to achieve therapeutic responses without eliciting the potential damaging
effects of TNF-α.
IFN-, secreted primarily by activated T cells, was also evaluated and is another
cytokine associated with inflammation and Th1 differentiation. Similar to what was
observed for TNF-α, our results demonstrate dose-dependent increases in IFN- in
response to ZnO NP (Figure 18A). This provides further evidence that ZnO NP can
induce pro-inflammatory, Th1-directed immune responses at concentrations below those
required to produce significant losses of T cell viability. These results are important as
IFN- is an important cytokine for promoting a Th1-mediated immune response, and Th1
cells are recognized as an essential cell subset for the effective elimination of cancer cells
in vivo. The narrow range in ZnO NP concentrations necessary to increase TNF-α and
IFN- reveals that parameters controlling ZnO NP toxicity, such as size, concentration,
etc. need to be carefully controlled if ZnO NP are to be considered for used for
therapeutic purposes.
The cytokine IL-12 is secreted primarily by activated monocytes, macrophages,
DC cells, and to a lesser extent, T cells. IL-12 is essential in skewing the Th1/Th2 T cell
responses toward a Th1-cell mediated immune response by inducing NK cells and T cells
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to secrete other Th1-directed cytokines and suppressing the humoral Th2-mediated
cytokines. Results from these experiments reveal that when PBMC are first primed by
addition of exogenous IFN-, significant increases in IL-12 are observed in response to
NP treatment (Figure 18C). These results suggest that a synergistic relationship between
ZnO NP and the priming signals necessary to promote IL-12 secretion (e.g. IFN-) may
occur in in vivo settings employing ZnO NP.
Importantly, our findings demonstrating that ZnO NP can induce TNF-α, IFN-,
and IL-12 in activated immune cells suggest that careful titration of ZnO NP-based
therapeutic interventions may be successful in elevating this key group of cytokines
important for eliciting a Th1-mediated immune response with effective anti-cancer
actions. Our results support other research demonstrating ZnO NP capable of inducing
other pro-inflammatory cellular responses (Gojova et al. 2007; Sayes et al. 2007; Wieder
et al. 2008), however this research is limited and to date, there have been no reports in
which the pro-inflammatory potential of ZnO NP in primary human immune cells have
been evaluated. Our results are of interest as they suggest the possibility of manipulating
the immune response for utility in enhancing cancer cell targeted killing at concentrations
of ZnO NP that do not cause significant cell death to normal cells.

In conclusion, results from these studies provide evidence demonstrating ZnO NP
induce toxicity in a cell-specific and proliferation dependent manner with rapidly
dividing, higher-ROS producing cells being the most susceptible, presumably in response
to intracellular NP-mitochondrial interactions and mitochondrial damage, and quiescent
cells being the least sensitive. Results also indicate cell-type dependent NP association
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and intracellular localization, although additional research is required to further elucidate
selective phagocytic/endocytic ZnO NP mechanisms based on specific cell susceptibility
to ZnO NP-induced toxicity. ZnO NP increased the expression of the pro-inflammatory
cytokines IFN-, TNF-α, and IL-12 at concentrations that shown minimal toxicity to
primary NK, T and B cells. Manipulation of the immune response is a key element for the
effective treatment of disease, and many current treatments for cancer, infection and
autoimmunity are immunobased therapeutics (Becker 2006; Miao 2007).These findings
suggest ZnO NP may direct Th1 mediated immune responses in vitro and illustrate the
potential utility of ZnO NP for the treatment of diseases such as cancer, which is better
eradicated by the development of a vigorous Th1-mediated immune response. Future
studies will be required to investigate the effects of higher concentrations of ZnO NP on
pro-inflammatory cytokine secretion and evaluate NP effects on other cytokine profiles.
Additionally, expansion of these studies should include investigating mechanisms of ZnO
NP adsorption, specifics of cellular uptake and intracellular localization, and the
contribution of particular elements of the biotic environment that affect ZnO NP toxicity.
Collectively, the findings presented in this research provide significant information that
may be ultimately exploited for utilizing ZnO NP in the treatment of disease and
developing next generation NP-based nanomedicines leading to improvements in
lifespan, tumor growth inhibition, and decreased lethality.
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APPENDIX
Figures and Tables
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Figure 1. Transmission electron microscopy (TEM) image and size distribution of ZnO
NP. A) For experiments conducted on all eukaryotic cells, ZnO NP were spun out of
DEG, washed with ethanol, dried into powder form, and resuspended in an aqueous
phosphate buffered saline (PBS) solution to desired stock concentration (mM). B) Plot
showing particle size distribution where average NP size was determined to be 13 nm.
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Figure 2. Effect of micron-sized bulk ZnO versus ZnO NP on CD4+ T cell
viability. Purified CD4+ T cells (>96%) were cultured at 1 x 106 cells/mL and treated with
varying concentrations of 13 nm ZnO NP or bulk ZnO. After 24 h of culture, cells were
dually stained with PI and a FITC-labeled anti-CD4 antibody. 10,000 events gated on
CD4+ T cells were analyzed for changes in PI staining to allow quantification of cell
death. NP were excluded from analysis based on their absence of fluorescent signal. Data
from four independent experiments is presented and error bars depict standard error. To
assess differences in viability between bulk ZnO and ZnO NP at each concentration, data
was analyzed using a repeated measures analysis of variance (ANOVA) and asterisks
denote statistically significant differences (p <0.05).
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Figure 3. Dot plots of relative viability of bacterial suspensions by flow cytometry.
Samples of bacteria were prepared, stained and analyzed using a 2-color live/dead
BacLight® viability kit allowing for a two-parameter comparison of green and red
fluorescence emission. Prior to sample analysis, the assay was validated using known
mixtures of dead and live control cells. Bacteria were gated by forward scatter and side
scattering light properties (R1, not shown) and nanoparticles excluded from analysis
based on their absence fluorescence (R2, not shown). The R3 region depicts the region
containing dead cells and the R4 region depicts the region containing live cells. A) The
relative viability of E. coli (>30% loss of viability) treated with 5 mM ZnO nanoparticles
for 15 h. B) The relative viability of S. aureus (>59% loss of viability) treated with 2 mM
ZnO nanoparticles for 15 h.
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Figure 4. ZnO NP toxicity to unactivated and activated primary human CD4+ T cells. A)
Human peripheral blood CD4+ T cells were isolated (purity >95%) and activated with
anti-CD3 antibodies, a combination of anti-CD3 and anti-CD28, or left unactivated.
Cultures were concurrently treated with varying concentrations of ZnO NP for 22-24 h
and cell viability determined using flow cytometry and PI uptake (means  standard
error, n=6). To evaluate the relationship between cell cycle state and ZnO NP toxicity,
data was analyzed using repeated measures analysis of variance and model based means
post hoc test (p < 0.05). The two study factors are cell cycle state (unactivated,
moderately activated with anti-CD3, and fully activated with anti-CD3/anti-CD28) and
ZnO NP concentration (0 mM, 1 mM, 5 mM and 10 mM). Following overall statistical
significance, cell viability (%) was compared among activation states at each
concentration level using model-based estimates and standard errors. B) Verification of T
cell activation was determined by concurrently monitoring expression of membrane
CD40L protein using flow cytometry (means  standard error, n=5).
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Figure 5. Differential cytotoxic effects of ZnO NP on cancerous T cell lines and primary
T cells. A) Jurkat, Hut-78 T cell lines, or normal primary T cells were treated with
varying concentrations of ZnO nanoparticles for 22–24 h and viability determined by
monitoring PI uptake using flow cytometry. Data from seven (Jurkat), three (Hut-78), and
four (normal CD4+ T cells) independent experiments is presented and error bars depict
standard error. Data was analyzed using a repeated measures ANOVA and model based
means post test. Statistical comparisons were made between each cancer cell line and
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primary T cells at 0.1 and 0.5 mM ZnO NP with significance levels defined as p < 0.05
and indicated by an asterisk. B) Jurkat and primary T cell viability was assessed using the
LIVE/DEAD™ Viability/Cytotoxicity Kit for mammalian cells (Invitrogen, Eugene, OR).
Following ZnO NP exposure for 24 h, cells were stained with calcein AM (green
fluorescence) and ethidium homodimer-1 (red fluorescence) to differentiate between live
and dead cells, respectively. Data from a representative experiment is presented with
error bars depicting standard error, n = 3. A two-way analysis of variance combined with
a model based means test indicates significant differences in viability between Jurkat and
primary T cells for all NP concentrations tested (asterisk denotes p < 0.0001).
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Figure 6. Differential ZnO NP cytotoxicity between naïve and memory T cells. Human
peripheral blood PBMC were left untreated or treated with 10 mM ZnO NP (8 nm) for
22-24 h and viability determined by monitoring PI uptake using flow cytometry. T cells
were defined as CD3+, naïve T cells as CD3+, CD45RA+, and memory T cells as CD3+,
CD45RO+ events. Data from three independent experiments is presented and error bars
depict standard error. Asterisks denote statistically significant differences (p < 0.05)
between NP treatment groups as determined using as a one-way repeated measures
ANOVA.

95

Figure 7. Kinetics of ZnO NP toxicity on normal primary T cells and Jurkat T leukemia
cells. Freshly isolated CD4+ T cells (purity > 96%) were treated with 10 mM ZnO NP
and Jurkat T cells were treated with 0.5 mM ZnO NP for varying times and viability
determined using PI uptake and flow cytometry. Means  standard error from
representative experiments are presented (n=3).
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Figure 8. Differential cytotoxic effects of ZnO NP on primary immune cell subsets. A)
PBMC were treated with varying concentrations (0.5 mM-10 mM) of 8 nm ZnO NP for
24 h and viability of CD3+ T cells, CD4+ T cells, B cells, NK cells, and monocytes
present in PBMC cultures determined by monitoring PI uptake and flow cytometry. Data
from three (CD3+, NK cell and monocyte) and four (B cell) independent experiments is
presented, with error bars depicting standard error. Data presented for purified CD4+ T
cells (>96%) is from one representative experiment done in triplicate with error bars
depicting standard error. Asterisks denote statistically significant (p < 0.05) differences
between CD3+ T cells, B cells, NK cells and monocytes at indicated NP concentrations as
determined using a repeated measures ANOVA. B) ZnO NP toxicity on purified human
primary monocytes. Isolated CD14+ monocytes were treated with varying concentrations
of ZnO NP (0.0625 -1 mM) and viability assessed using the Alamar Blue cytotoxicity
assay with error bars representing standard error (n=4).
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Figure 9. TEM images of different sized ZnO nanoparticle made by varying the
hydrolysis molar ratio. A) 4 nm sized ZnO NP made using a water to zinc acetate ratio of
2.4. B) 8 nm sized ZnO NP made using a water to zinc acetate ratio of 6.1. C) 13 nm
sized ZnO NP made using a water to zinc acetate ratio of 12.2. D) 20 nm sized ZnO NP
made using a water to zinc acetate ratio of 36.6. E) Corresponding size distribution of the
samples shown in panels A-D as determined by TEM. F) XRD patterns of the ZnO
samples shown in panels A-D. Reference data for wurtzite ZnO is shown along the
bottom.
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Figure 10. Effect of NP size on cytotoxicity. A) Purified human CD4+ T cells (>97%
purity) were left untreated or incubated with three different sizes (4nm, 13nm, and 20
nm) of ZnO NP at a final concentration of 5 mM. Following culture for 22-24 h, viability
was determined using PI uptake and flow cytometry, n=4. B) Cytotoxicity studies in
purified human CD4+ T cells were performed using varying concentrations (1-10 mM) of
4nm and 20 nm sized ZnO NP, n=4. Error bars depict standard error and asterisks
indicate statistically significant differences (p < 0.05) as determined by repeated
measures ANOVA.
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Figure 11. Cellular production of ROS following ZnO NP exposure. ROS generation
was evaluated in primary T cells and monocytes and in the transformed Hut-78 T cell line
following 18-24 h of ZnO NP exposure using the oxidation sensitive dye DCFH-DA and
flow cytometry. A & C) Representative histograms depicting ROS production in primary
T cells and monocytes. Assays were performed using freshly obtained whole blood in
which red blood cells were removed following NH4Cl lysis. T lymphocytes and
monocytes were gated based on staining with fluorescently labeled CD3 and CD14 Ab
and the oxidation product of DCFH-DA detected using the FL1 detector. B) Histogram
depicting ROS production in the transformed Hut-78 T cell line. In each histogram, the
grey line depicts fluorescence in DCFH-DA loaded cells while the black line depicts
fluorescence in DCFH-DA loaded cells treated with ZnO NP for 18 h (A & C) or 24 h
(B). Numbers in parentheses indicate the percentage of ROS positive cells.
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Figure 12. NP size affects ROS production in PBMC. PBMC were treated with two
different concentrations (5 mM and 10 mM) of 4 nm, 13 nm and 20 nm ZnO NP for 3 h
and ROS production evaluated using a fluorescent microplate reader. Data from one
representative experiment is shown (n = 3) and error bars depict standard error. Data was
analyzed using a 2-way ANOVA and asterisks denote statistically significant differences
as defined by p < 0.05.
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Figure 13. Quenching of ROS rescues T cells and monocytes from ZnO NP-induced
cytotoxicity. Purified peripheral blood CD14+ monocytes ( 96% purity) and CD4+ T
cells ( 95% purity) were pretreated for 4-6 h with 5 mM N-acetyl cysteine (NAC) or
vehicle control and subsequently cultured with ZnO NP, or left untreated, for 22-24 h.
Viability was assessed using the Alamar Blue cytotoxicity assay. A) Purified monocytes
treated with 0.125 mM ZnO NP  5 mM NAC, n=3. B) Isolated CD4+ T cells treated
with 5 mM ZnO NP  5 mM NAC, n=3. Data for both T cells and monocytes was
analyzed using a 2-way ANOVA; asterisks denote statistically significant differences (p
< 0.05) and error bars depict standard error.
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Figure 14. The activation of T cells promotes NP association. Primary CD4 + T cells
(>96% purity) were left untreated or activated with immobilized CD3/CD28 antibodies
and cultures concurrently treated with 5 mM FITC encapsulated ZnO NP for 4 h. Cells
were stained using an ECD-labeled CD4 Ab. Using flow cytometry, 10 000 events gated
on CD4+ cells were analyzed for changes in FITC fluorescence and data from a
representative histogram is presented. A) Resting T cells cultured with FITC
encapsulated NP and panel. B) Activated T cells cultured with FITC encapsulated NP.
Inset numbers depict the percentage of FITC positive cells. The positioning of the
quadrant on the x-axis was determined using T cells cultured without fluorescently
labeled NP and set so 1% of cells appeared in quadrant 2. C) Depicts a dose-dependent
increase in NP association with T cells, n = 3 with error bars depicting standard error.
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Figure 15. Uptake of FITC-ZnO particles by Jurkat T cells. Confocal fluorescence
microscopic images of Jurkat T cancer cells treated with 0.25 mM FITC-ZnO particle
(green fluorescence) for 8 h and stained with a PE-conjugated Ab specific to CD3 cell
surface protein (red fluorescence) with extensive washing to remove extracellular NP.
Panel A depicts FITC-ZnO particles alone (after identical washing steps as samples
containing cells) with an arrow indicating a typical particle of ~200 nm. Panels B-D show
consecutive cell images/slices of a single cell. In panel C, an internalized particle of
expected 200 nm size is indicated by an arrow and orthogonal viewing was used to
confirm particle intracellular localization.
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Figure 16. ZnO NP induce apoptosis in Jurkat T cells. Cells were left untreated, treated
with 0.3 mM ZnO NP for 20 h, or treated with 100 nM okadaic acid for 20 h (positive
control) and stained with a green fluorescent annexin V antibody to detect apoptotic
membranes and the red fluorescent dye PI to detect permeable membranes using the
Vybrant apoptosis assay kit #2 (Molecular Probes). Cells were visualized by confocal
microscopy and representative images are shown. Panels A-C depicts control cells not
treated with NP. Panel A shows control differential interference contrast (DIC image),
panel B shows control DIC image with green and red fluorescence overlay, and panel C
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shows control green and red fluorescence image. Panels D-G depict cells treated with NP;
panel D shows NP treated DIC image, panel E shows NP treated DIC image with green
and red fluorescence overly, panel F shows NP treated green and red fluorescence image,
and panel G shows an additional green and red fluorescence image of NP treated cells of
lower magnification.
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Figure 17. Detection of apoptotic morphological changes in Jurkat cells treated with ZnO
NP. Cells were left untreated (A), or treated with 100 nM okadaic acid for 20 h as a
positive control for apoptosis (B), or treated with 0.3 mM ZnO NP for 20 h (C) and
stained with acridine orange and visualized by fluorescent microscopy. Arrows indicate
typical apoptotic cells characterized by a shrunken appearance and condensed or
fragmented nuclei.
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Figure 18. ZnO NP treatment increases pro-inflammatory cytokine production in
PBMCs. Primary human peripheral mononuclear cells were left untreated or treated with
three concentrations of 8 nm ZnO NP (0.05 mM, 0.1 mM and 0.2 mM), both alone or
with the addition of exogenous IFN- (1000 U/mL) for 38 h. Cytokine production was
evaluated by ELISA and measured in pg/mL. Data was analyzed using a 2-way ANOVA
with error bars depicting standard error from the mean. Asterisks denote statistically
significant differences as defined as p < 0.05. ** = significant differences between all
treatment groups (including NT), * = significant differences compared to 0.05 mM and
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NT. No significant differences were observed for any samples not primed with
exogenous IFN-.
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Figure 19. Effect of SnO2 NP and CeO2 NP on T cell viability. Purified human CD4+ T
cells (> 97% purity) were left untreated or incubated with two different concentrations of
either SnO2 NP or CeO2. Following culture for 22-24 h, viability was determined using PI
uptake and flow cytometry, n=3 from one representative experiment and error bars depict
standard error. A) T cells left untreated or treated with 5 mM SnO2 NP. B) T cells left
untreated or treated with 5 mM CeO2 NP.
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Table 1. Freshly isolated PBMC were treated with either 1mM or 5 mM of 8 nm sized
ZnO NP and ROS production measured using the oxidation sensitive fluorescent probe,
DCFH-DA. Following NP treatment for 6 h or 20 h, cells were stained with fluorescently
labeled CD3 (T cells) and CD14 (monocytes) Ab and loaded with DCFH-DA. Flow
cytometry was used to simultaneously evaluate ROS production and distinguish T cells
and monocytes present in PBMC cultures. Values represent the percentage of ROS
producing cells ± standard error from the mean.

Table 1.

NP-induced ROS production

Time

*Cells

0 mM NP

1 mM NP

5 mM NP

6h

T cells

1.4%  0.1%

1.3%  0%

***ND

6h

mono

1.4%  0.13%

19.3%  2.6%

***ND

20h

T cells

6.5%  2.8%

3.4%  1.1%

38.5%  1.8%

20h

mono

8.1%  3.4%

**<3% viable cells

**<1% viable cells

* CD3+ T cells and CD14+/CD3- monocytes (monos) present in PBMCs
** NP-induced cell destruction precludes collection of FS/SSC gated cellular events and subsequent
ROS signal
***Values not determined (ND)
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Table 2. Freshly isolated PBMCs were left untreated or exposed to 5 mM FITCencapsulated ZnO NP for 16h. The cell mixture was then stained with fluorescently
labeled CD3, CD4, CD19, CD14 Ab to identify subsets, washed to remove excess Ab and
unbound NP, and the level of NP association determined based on FITC fluorescent
signal using flow cytometry. Data was obtained by gating on 10 000 events, n=3.

Table 2.

NP association with various immune cells
Control (% / MFI)a

+ FITC-NP (% / MFI)b

CD3+ T cells
1.79% / 1.15
84.2% / 9.84
CD4+ T cells
1.61% / 1.23
82.5% / 14.1
+
CD19 B cells
2.0% / 2.85
78.1% / 9.61
CD14+ Monocytes
1.7% / 5.80
98.0% / 131.2
a
Values shown represent the background autofluorescence signal for control cells (percent
FITC positive cells/mean fluorescent intensity (MFI)
b
The percentage of FITC positive cell and MFI for cells treated with FITC-doped ZnO

NP
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